Host and pathogen genomics of severe pediatric infections by Asgari, Samira
POUR L'OBTENTION DU GRADE DE DOCTEUR ÈS SCIENCES
acceptée sur proposition du jury:
Prof. B. Deplancke, président du jury
Prof. J. Fellay, directeur de thèse
Prof. J.-L. Casanova, rapporteur
Prof. P. McLaren, rapporteur
Dr J. Rougemont, rapporteur
Host and pathogen genomics of severe pediatric infections
THÈSE NO 6656 (2016)
ÉCOLE POLYTECHNIQUE FÉDÉRALE DE LAUSANNE
PRÉSENTÉE LE 27 AVRIL 2016
 À LA FACULTÉ DES SCIENCES DE LA VIE
GROUPE FELLAY
PROGRAMME DOCTORAL EN BIOTECHNOLOGIE ET GÉNIE BIOLOGIQUE 
Suisse
2016
PAR
Samira ASGARI
? ?
? ????
?????????????????
A great many people have contributed to the completion of this dissertation. I owe my 
gratitude to every one of these people who have made my graduate experience a period 
that I will cherish forever. 
Foremost, I would like to thank my advisor, Dr. Jacques Fellay, whose expertise, 
knowledge and thoughtful feedback have guided me through my graduate studies. I 
appreciate the freedom he has given me to explore on my own, and the guidance he 
provided when my progress faltered. Jacques’ encouragement, understanding and 
patience added considerably to my overall experience.  
I would like to extend my thanks to Dr. Didier Trono, my mentor. Didier’s insightful advice 
was pivotal in my decision to follow a career in computational biology and his meticulous 
suggestions have always helped me to clarify my ideas. 
I would like to acknowledge Dr. Luregn Schlapbach for his crucial role in the recruitment of 
patients, Dr. Dominique Garcin for his indispensable role in experimental validation of our 
findings and Dr. Caroline Tapparel for her expert input in designing the experiments. 
My sincere thanks also go to our patients and their families. Without their trust and 
participation this work would never have been possible.  
I would like to thank many past and current colleagues who, directly or indirectly, 
contributed to completion of this work. In particular, I would like to thank my colleagues in 
Fellay lab. Their thought-provoking discussions helped me to focus my ideas, their 
constructive criticisms held me to the highest of standards at all stages of my research, and 
their humour and conviviality made the day-to-day work experience filled with joy. This is 
by necessity an incomplete list, in no particular order: Marisa Marciano wynn, Paul 
McLaren, Thomas Junier, Istvan Bartha, Christian Hammer, Nimisha Chaturvedi, 
Alessandro Borghesi, Petar Scepanovic, Christian Thorball, Ana Bittencourt Piccini, 
Caroline Perraudin, Jennifer Makovkina, Margalida Rotger and Antonio Rausell. 
I’m blessed with numerous extraordinary friends to whom I owe some of the happiest 
memories of my life. Their support helped me overcome the moments of crisis and their 
craziness helped me stay sane in difficulties. My deepest appreciation goes, in no 
particular order, to: Lionel, Amin, Somayyeh, Mahdi, Farhang, Victoria, Arefeh, Azadeh, 
Hanieh, Mahdieh and Vahideh. 
Finally, I owe my deepest gratitude to my family. They have been a constant source of 
love, support and strength throughout my life. My heart-felt gratitude goes to my parents, 
my sister and my brother. This dissertation is dedicated to them. 

? ?
?????????
Infectious diseases are among the leading causes of human morbidity and mortality, with 
the greatest burden felt in the pediatric population. For any infectious disease, only a 
fraction of the exposed individuals develop clinical symptoms. These inter-individual 
differences can be due to variation in pathogen virulence or in host susceptibility. The 
recent advent of high-throughput sequencing (HTS) technology has enabled studies of both 
human and pathogen genetic factors that have the potential to influence infectious 
diseases pathogenesis and alter clinical presentation.  
In this thesis, I present a set of genomic studies that used HTS to dissect the genetic basis 
of life-threatening infections with Pseudomonas aeruginosa (P. aeruginosa) and respiratory 
syncytial virus (RSV). This work provides conclusive evidence for the role of rare human 
genetic variants in susceptibility to life-threatening P. aeruginosa and RSV infections in 
previously healthy children. Furthermore, in an attempt to determine the role of viral genetic 
factors in severe presentations of RSV infection, I established a framework for exploring 
RSV genetic variation using HTS technology and bioinformatic analysis. 
Together, theses studies demonstrate that current genomic technology, bioinformatic 
analysis and functional follow-up have the potential to give us novel insight into the 
molecular basis of host-pathogen interactions and infectious disease pathogenesis.  
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Les maladies infectieuses comptent parmi les causes principales de morbidité et de 
mortalité chez l’homme, et la population pédiatrique est particulièrement touchée. Pour une 
maladie infectieuse donnée, seule une fraction des individus exposés développent des 
symptômes cliniques. Ces différences interindividuelles peuvent être dues à des variations 
dans la virulence du pathogène ou dans la susceptibilité de l'hôte. Les récents 
développements dans le domaine du séquençage à haut débit ont ouvert la voie à l'étude 
des facteurs génétiques de l'humain comme des pathogènes - des facteurs qui ont le 
potentiel d'influencer la pathogenèse des maladies infectieuses ou d'en modifier la 
présentation clinique. 
Dans cette thèse, je présente une série d'études reposant sur le séquençage à haut débit, 
qui ont pour objectif d’élucider les bases génétiques d'infections potentiellement mortelles 
dues à Pseudomonas aeruginosa (P. aeruginosa) et au virus respiratoire syncytial (RSV 
pour respiratory syncytial virus). Ce travail a permis de mettre en évidence le rôle de 
variations génétiques humaines rares dans la susceptibilité de certains enfants sans 
facteurs de risque établis de développer une maladie potentiellement mortelle suite à une 
infection par P. aeruginosa ou RSV. D’autre part, j'ai développé un modèle d’exploration 
des variations génétiques du RSV reposant sur le séquençage à haut débit et l'analyse 
bioinformatique. 
Ces études démontrent que la combinaison des technologies génomiques les plus 
récentes, d’analyses bioinformatiques et d’un suivi fonctionnel permet de fournir de 
nouvelles informations sur les bases moléculaires des interactions entre hôte et 
pathogène, ainsi que sur la pathogenèse des maladies infectieuses. 
 
Mots-clés: maladies infectieuses, Pseudomonas aeruginosa, virus respiratoire syncytial, 
population pédiatrique, génomique humaine, génomique virale, séquençage à haut débit, 
immunodéficience primaire 
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Heritable factors have been considered to play a role in infectious diseases for a long time. 
Tuberculosis and leprosy, for example, were long considered heritable diseases as they 
were usually clustered within a household (1, 2) . With Pasteur’s discovery of microbes, 
and the observations supporting the communicable nature of infectious diseases, the focus 
moved from host to pathogen. The role of human genetics in the outcome and clinical 
features of infectious diseases was highlighted again by multiple observations that 
exposure to a pathogen, while necessary for infection, is not sufficient, and that not all 
exposed individuals develop overt disease. The first such observation was Charles 
Nicolle’s discovery of ”asymptomatic infections“ between 1911 and 1920. Nicole realized 
that apparently healthy individuals can be carriers of replicating typhus microbes 
(Rickettsia bacteria) in their blood and can transmit the disease while remaining completely 
asymptomatic (3, 4) . In 1927, the accidental infection of a population with Mycobacterium 
tuberculosis in Lubeck, Germany, caused severe disease and death in some individuals, 
while others remained unaffected (5) . Such observations suggested a potential role for 
human genetics in susceptibility and outcome of infectious diseases (6–8) . More evidence 
for the importance of genetic variation in infectious disease heterogeneity comes from early 
twin and adoptee studies. In 1978, Comstock showed that in a cohort of twins with 
tuberculosis, the disease concordance is significantly higher in monozygotic than in 
dizygotic twins (9) . In a landmark study published in 1988, Sorensen et al. showed that 
adopted children have a markedly higher risk of premature death form infection if one of 
their biological parents also died from an infectious disease and concluded: "... premature 
death in adults has a strong genetic background, especially death due to infections and 
vascular causes” (10) . Together, these early studies strongly support the hypothesis that 
the host genetic profile plays an important role in individual susceptibility to infection.  
??? ?????????????????????????????
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The twin and adoptee studies described above were not designed to provide information on 
the molecular basis of the observed variability in susceptibility to pathogens. In 1952, 
Ogden Bruton described the first documented case of a primary immunodeficiency (PID), 
X-linked agammaglobulinemia (XLA). PIDs are inborn errors of immunity that make 
affected subjects highly susceptible to infectious agents that rarely cause severe outcomes 
in the vast majority of patients. Bruton described a boy with recurrent invasive 
pneumococcal disease and who lacked serum gammaglobulins (11, 12) . It took more than 
? ???
50 years to discover the gene underlying XLA. By 1990, candidate gene studies and 
genome-wide linkage analysis studies had become standard approaches to study host 
genetic susceptibility to infectious diseases. They identified a number of genetic regions 
associated with susceptibility to several infections, including malaria, HIV, tuberculosis, 
invasive pneumococcal disease and leprosy (13, 14) . However, a clear limitation of the 
linkage approach is the requirement to recruit families that are potentially informative about 
infectious disease phenotypes. In candidate gene studies, the choice of target genes was 
either based on evidence from animal studies, genome-wide scans and clinical 
observations, or simply based on known biological relevance. For example, the human 
leukocyte antigen (HLA) locus on chromosome 6 has been under intense scrutiny (15–18) . 
Candidate gene association studies are limited by a need for a pre-existing hypothesis as 
well as low level of reproducibility. Despite their limitations, findings of genome-wide 
linkage studies and candidate gene studies, along with in vivo studies using different 
strains of inbred mice shed some light on the molecular basis of susceptibility to several 
infectious diseases.  
????? ???????????????????????????????????????
In the first decade of the twenty-first century, the completion of human genome project 
along with the HapMap project and the advancement in microarray-based high-throughput 
technologies made it possible to genotype hundreds of thousands of common 
polymorphisms in the genome of a large number of study participants. These technological 
and conceptual advances made it possible for the first time to explore the entire human 
genome without a need to make assumptions about the location of the causal variant(s). 
The first GWAS was published in 2005  (19) . In 2007, the first GWAS of an infectious 
disease was performed on human immunodeficiency virus-1 (HIV-1) virus load. In this 
study, Fellay et al. described a series of single nucleotide polymorphisms (SNPs) in the 
major histocompatibility complex (MHC) region that associated with control of viral load and 
disease progression in a European population (20) . GWAS have now been performed for 
multiple infectious diseases, and some identified new associations between human genetic 
variants (mainly SNPs) and the disease phenotype. A large GWAS conducted by the 
International HIV Controllers Study in 2010, confirmed the previously published 
associations with HIV-1 control, and reported associations for 6 additional SNPs: two in 
European and four in African-American populations (21) . Another example of GWAS 
success is the detection of an association between SNPs in the IL28B gene region and two 
phenotypes of hepatitis C virus infection: response to interferon-based treatment and 
spontaneous clearance (22) . In 2009, Zhang et al. reported the first GWAS of leprosy 
susceptibility in 11000 individuals of Chinese ancestry. The study identified multiple strong 
associations, many of which clustering in innate immune pathways (23) . The NHGRI-EBI 
Catalogue of genome-wide association studies contains 76 studies describing 682 
associations in 46 infectious phenotypes that were published between 2007 and April 2015 
(http://www.ebi.ac.uk/gwas/home). There are now published GWAS for HIV-1 (21, 24–42) , 
epstein-barr virus (EBV) (43) , human papilloma virus (HPV) (44) , tripanosoma cruzi (45) , 
hepatitis C virus (22, 46–60) , tuberculosis (61–65) , malaria (66–69) , hepatitis B virus 
(70–79) , influenza virus (80, 81) , bacteraemia (82–84) , leprosy (23, 85, 86) , 
???
leishmaniasis (87) , meningococcal disease (88) , shingles (89) , dengue fever  (90) , and 
Creutzfeldt–Jakob disease (91, 92) .  
GWAS have once again confirmed the important role of host genetics in shaping human 
response to various infections. However, for statistical reasons, the GWAS approach can 
only be successful for common infectious phenotypes associating with alleles that are 
relatively common in the population. Indeed, a GWAS is a statistical test of association that 
tests the null hypothesis: “none of the SNPs in this dataset is associated with the trait of 
interest” against the alternate hypothesis: “at least one of the SNPs in this dataset 
associates with the trait of interest”. In a GWAS with a set number of observations the 
power to reject the null hypothesis when the alternate is true depends on sample size, 
effect size and allele frequency. The standard to declare a GWAS hit significant at genome-
wide level is a combined P value (including ‘initial discovery’ GWAS and replication 
cohorts) of < 5e–8. For less common infectious disease phenotypes, the required sample 
size to achieve such significance thresholds is unrealistically large, making it very difficult 
or even impossible to recruit enough study participants. Additionally, even with large 
sample sizes, a GWAS will not be able to find novel or rare variants, as SNP arrays focus 
on previously known genetic polymorphisms with the majority of the variants having a 
minor allele frequency above 1 to 5% (Figure 1.1). Despite these limitations, GWAS 
improved our understanding of genotype-phenotype relationships in infectious diseases 
and in some cases led to the discovery of new genetic association in previously 
unsuspected regions of genome.
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In  2005, the first high-throughput sequencer became commercially available (the 454 
machine, from Life Sciences). The technology used, called pyrosequencing, is based on 
sequencing-by-synthesis, in which a DNA sequence serves as template and a DNA 
polymerase is used to extend a sequencing primer by incorporating nucleotides that form a 
growing sequence complementary to the template. This was the first example of what 
became known as “next generation sequencing” methods, which used parallelization to 
produce more reads in a faster and cheaper way (94) . The rapid advancement of HTS 
technologies coupled with the plummeting cost of sequencing allowed the widespread use 
of this technology in many fields of biology and medicine, including infectious disease 
biology, during the past five years. HTS in combination with appropriate study design and 
sampling has made the non a priori screening of entire human genomes a reality. A 
successful example was the use of exome sequencing by Byun et al. in 2010 to diagnose a 
child with fatal classic Kaposi sarcoma (KS), a neoplasm caused by human herpes virus 8 
(HHV8). They reported a homozygous splice-site mutation in STIM1 (chromosome 11 
position 4103413, hg19) that was causing immunodeficiency 10 (IMD10) (95) . The same 
year, Bolze et al. reported the use of a combination of exome-sequencing and linkage 
analysis in a large kindred with four affected members to identify a homozygous 
nonsynonymous mutation in FADD as the cause of an autosomal recessive disorder with 
biological features of autoimmune lymphoproliferative syndrome (ALPS) (96) . These two 
studies were the first example of using HTS in a small number of patients to decipher the 
genetic basis of rare infectious disorders. Since 2010, there has been an exponential 
increase in the number of genes known to confer unusual susceptibility to one or more 
pathogens. Table 1.1 lists these genes discovered since 2010 using HTS.  
In brief, recent findings suggest that the use of exome or whole genome sequencing has 
enormous potential to identify novel variants involved in acquisition or progression of 
infectious diseases.  
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Gene Mutation 
Inh
. 
Phenotype Study population Ref. 
FADD Missense AR 
 Severe Infections, 
autoimmunity 
One 
consanguineous 
pedigree 
 (96)  
MAGT1 
Nonsense, 
frame-shift 
XR 
Severe viral infections, T cell 
deficiency, CD4 lymphopenia 
Two pedigrees  (97)  
ZBTB24 
Nonsense, 
missense 
AR 
B cell deficiency, dysmorphism, 
Immunodeficiency, 
Centromeric Instability, and 
Nine pedigrees (six 
consanguineous) 
 (98)  
? ???
Facial Anomalies Syndrome 
Type 2 (ICF2) 
STAT1 
Missense 
(GOF) 
AD 
Chronic mucocutaneous 
candidiasis, autoimmune 
thyroiditis 
Multiple pedigrees 
 (99, 
100)  
GATA2 
Missense, 
splice site, 
frame-shift, 
nonsense 
AD 
Infections, monocytopenia, B-
cell and NK-cell lymphopenia, 
predisposition to acute myeloid 
leukemia  
Pedigrees and 
sporadic cases  
 
(101
–
104)  
RHOH Nonsense  AR 
Various infections, T cell 
deficiency  
One 
consanguineous 
pedigree 
 
(105)  
CARD11 
Missense 
(GOF) 
AD B cell lymphocytosis 
One pedigree and 
one sporadic case 
 
(106)  
MCM4 
Splice site, 
fame-shift 
AR 
Adrenal insufficiency, NK cell 
deficiency 
Seven 
consanguineous 
pedigree 
 
(107, 
108)  
POLE Splice site AR 
 Bacterial infection, facial 
dysmorphism, 
immunodeficiency, livedo, and 
short stature (FILS syndrome) 
One 
consanguineous 
pedigree 
 
(109)  
TBK1 Missense  AD Herpes simplex encephalitis Two sporadic cases 
 
(110)  
CARD14* 
Splice site, 
missense, 
in-frame 
deletion 
(GOF) 
AD Psoriasis  Six pedigrees  
 
(111
–
113)  
PLCG2 
Missense, 
large 
deletion 
(GOF) 
AD 
Recurrent infections, low 
antibody levels, autoimmunity, 
cold urticaris 
Five pedigrees 
 
(114, 
115)  
PIK3R1 Nonsense  AR 
Colitis, absent B cells, 
agammaglobulinemia 
One 
consanguineous 
pedigree 
 
(116)  
ADAR Missense AR Aicardi-Goutières syndrome 
Eight pedigrees (two 
consanguineous)  
 
(117)  
ISG15 Nonsense AR Mycobacterial disorder 
Two 
consanguineous 
pedigrees 
 
(118)  
RBCK1 
Nonsense, 
large 
deletion 
AR 
Invasive bacterial infections, 
chronic autoinflammation 
Two pedigrees (one 
consanguineous) 
 
(119)  
CD27 Nonsense AR 
Impaired T cell-dependent B-
cell responses, T-cell 
dysfunction, EBV infection 
One 
consanguineous 
pedigree 
 
(120)  
LRBA* 
Missense, 
nonsense, 
frame-shift, 
AR 
Autoimmunity, 
hypogammaglobulinemia  
Six consanguineous 
pedigree  
 
(121
–
? ???
large 
deletion 
123)  
MALT1 Missense  AR T cell deficiency 
One 
consanguineous 
pedigree 
 
(124)  
IL21R 
Missense, 
in-frame 
deletion 
AR 
Impaired T and B cells, 
impaired NK cell cytotoxicity 
Two 
consanguineous 
pedigrees 
 
(125)  
CARD11 
Deletion, 
Nonsense 
AR 
Deficient T cell function, 
distorted B cell populations 
Two 
consanguineous 
pedigrees 
 
(126, 
127)  
TNFRSF4 Missense AR Kaposi Sarcoma 
One 
consanguineous 
pedigree 
 
(128)  
TTC7A 
Splice site, 
missense 
AR 
Congenital multiple intestinal 
atresia 
Twelve pedigrees 
(two 
consanguineous), 
three sporadic 
cases 
 
(129, 
130)  
TRAF3IP2 Missense AR 
Chronic mucocutaneous 
candidiasis 
One 
consanguineous 
pedigree 
 
(131)  
TCF3 Missense AD 
B cell deficiency, 
agammaglobulinemia 
Eight pedigrees 
 
(132)  
TNFSF12 Missense AD 
Recurrent infections, B cell 
deficiency, 
agammaglobulinemia 
One pedigree 
 
(133)  
NFKB2 
Nonsense, 
frame-shift 
AD 
Recurrent infections, 
hypogammaglobulinemia, 
autoimmune features, adrenal 
insufficiency 
Two pedigrees 
 
(134)  
PRKCD 
Missense, 
Splice site 
AR 
Autoimmunity, systemic lupus 
erythematosus 
Three pedigrees 
(two 
consanguineous) 
 
(135
–
137)  
PIK3CD 
Missense 
(GOF) 
AD 
Recurrent respiratory and ear 
infections, decreased 
circulating B and T cells 
Eight pedigrees 
 
(138)  
RPSA 
Missense, 
frame-shift, 
nonsense 
AD 
Isolated congenital asplenia 
(ICA) 
Eight pedigrees 
 
(139)  
VPS45 Missense AR 
Congenital neutropenia, 
enlarged kidneys 
Seven 
consanguineous 
pedigrees 
 
(140, 
141)  
RTEL1 
Nonsense, 
missense, 
splice 
region 
AR 
Hoyeraal–Hreidarsson 
syndrome, short telomere, 
hypogammaglobulinemia, 
cytopenia 
Three pedigrees 
(one 
consanguineous) 
 
(142, 
143)  
IKBKB Nonsense, AR Multiple infections, One  
? ???
frame-shift hypogammaglobulinemia consanguineous 
pedigree, four 
sporadic cases 
(144, 
145)  
BCL10 Splice site  AR 
Combined immunodeficiency 
with B cell, T cell, and 
fibroblast defects 
One 
consanguineous 
pedigree 
 
(146)  
CTPS1 Splice site  AR 
Impaired proliferation of T and 
B cells t in response to antigen 
receptor-mediated activation 
Five pedigrees 
 
(147)  
TRNT1 
Missense, 
frame-shift, 
splice site  
AR 
B-cell immunodeficiency, 
periodic fevers, and 
developmental delay (SIFD) 
Eleven pedigrees 
(three 
consanguineous) 
and three sporadic 
cases 
 
(148)  
IL21 Missense AR 
Inflammatory bowel disease, 
reduced numbers of circulating 
CD19 positive B cells 
One 
consanguineous 
pedigree 
 
(149)  
CTLA4 
Nonsense, 
splice site  
AD 
Recurrent infection, 
hypogammaglobulinemia, 
disrupted T and B cell 
homeostasis 
Four pedigrees 
 
(150)  
TMEM173 
Missense 
(GOF) 
AD 
Upregulated type I IFN 
production, autoimmunity 
One pedigree 
 
(151)  
NLRC4 
Missense 
(GOF) 
AD 
Neonatal-onset enterocolitis, 
periodic fever, and fatal or 
near-fatal episodes of 
autoinflammation 
One pedigree 
 
(152)  
MAP3K14 Missense AR 
Recurrent infections, B cell 
lymphopenia, 
hypogammaglobulinemia, 
decreased NK cells 
One 
consanguineous 
pedigree 
 
(153)  
TPP1 
Missense, 
in-frame 
deletion 
AR 
Bone marrow failure, Hoyeraal-
Hreidarsson syndrome 
One pedigree 
 
(154)  
JAG1 
Nonsense. 
missense 
AR Invasive bacterial infections, 
severe congenital neutropenia 
Two 
consanguineous 
pedigrees 
 
(155)  
INO80 Missense AR 
Defective Immunoglobulin 
class-switch recombination 
Two sporadic cases 
 
(156)  
STAT4 Missense AD Kaposi Sarcoma 
One 
consanguineous 
pedigree 
 
(157)  
TADA2A Missense AR 
polyarteritis nodosa , stroke, 
hepatosplenomegaly, 
hypogammaglobulinemia, 
recurrent infections 
Multiple pedigrees 
 
(158, 
159)  
IFIH1 
Missense 
(GOF) 
AD 
Upregulated type I IFN 
production, Aicardi-Goutières 
syndrome 
Seven sporadic 
cases 
 
(160)  
? ???
IRF7 Missense AR 
Perturbed type I and type III 
IFN production 
One pedigree 
 
(161)  
DOCK2 
Missense, 
frame-shift 
AR 
Invasive infections; T cell 
lymphopenia; impaired T cell, B 
cell, and natural killer cell 
function; and defective 
interferon immunity 
Five pedigrees 
(three 
consanguineous) 
 
(162)  
RNF31 Missense AR 
Multiorgan autoinflammation, 
combined immunodeficiency 
One 
consanguineous 
pedigree 
 
(163)  
PGM3 
Missense, 
frame-shift 
AR 
Recurrent infections, eczema, 
and increased serum IgE levels 
Four 
consanguineous 
pedigree 
 
(164)  
MAP3K9 Nonsense AR 
Susceptibility to severe 
bacterial infection 
One 
consanguineous 
pedigree 
 
(165)  
RORC 
Missense, 
nonsense 
AR 
Mococutaneous candidiasis 
and mycobacteriosis 
Three 
consanguineous 
pedigrees 
 
(166)  
IRF3 Missense  AD Herpes simplex encephalitis 16 sporadic cases  
 
(167)  
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One hundred years after Charles Nicole’s description of  ”asymptomatic infections”, the 
genetic architecture of human susceptibility of most infectious diseases is still unknown. 
Genetic predisposition to infections can be found on a continuous spectrum from purely 
Mendelian (caused by fully penetrant alleles of high effect size in a single gene) to 
polygenic (caused by many variations of low effect size with incomplete penetrance in 
multiple genes) (3) . Till recently, rare infectious phenotypes were thought to cause 
susceptibility to multiple infections (e.g. most PIDs) and common infectious phenotypes 
cause susceptibility to one pathogen (e.g. susceptibilities discovered by GWAS). This view 
is consistent with ”rare variant-rare disease and common variant-common disease” 
hypothesis. This model gained experimental support from identification of rare monogenic 
variants as the genetic basis of PIDs and from a large number of GWAS showing an 
association between multiple common variants and common infections. However, this 
model cannot explain the rare PIDs that predispose to only one infection (or even to only 
primary infection) with one pathogen (8, 168) .  
The first two PIDs conferring predisposition to a single infectious agent to be described 
were epidermodysplasia verruciformis (EV), and X-linked lymphoproliferative disease 
(XLP). EV is an extremely rare disorder that predisposes to  wart-like skin lesions and skin 
cancer. It is an interesting, but certainly not unique example of such infectious phenotypes. 
EV is caused by a specific group of HPV that are harmless in the general population. The 
genetic origin of EV was suspected since 1933 and its viral etiology was established in 
1946 (169) . In 2002, recessive mutations in TMC6 and TMC8 were described as EV-
causing, and two years later EV was added to the international list of PIDs (170) . Even 
though EV as a clinical entity was known even before XLA, described in 1952 as the first 
? ???
PID, the lack of overt immunological phenotype and susceptibility to only one infection 
prevented EV to be recognized as a PID at that time (168) . Mutations in SAP were 
described in 1998 as the genetic basis of XLP, a rare disease occurring in individual 
carrying the mutation upon infection with EBV (171) . XLP is an example of a Mendelian 
infectious disease with variable phenotype, as patients can develop hemophagocytosis, 
lymphoma, or hypogammaglobulinemia (168) . Mendelian Susceptibility to Mycobacterial 
Disease was the first example of Mendelian susceptibility to a coherent group of 
pathogens, and the genetic etiology of the disease - recessive mutations in IFNGR1 - was 
first described in 1996 (172, 173) . A more recent example of Mendelian susceptibility to a 
single pathogen is chronic mucocutaneous candidiasis (CMC), which is the manifestation 
of unusual susceptibility to the commensal fungus Candida albicans and segregates as 
recessive or dominant due to mutations leading to impaired IL-17 immunity (174) .  
The notion of incomplete penetrance adds another layer of complexity to the understanding 
of host genetic susceptibility to infections. The monogenic architecture of susceptibility to 
one or a narrow range of infections can indeed be obscured when clinical symptoms are 
not present in all carriers of the mutant alleles. A prime example is herpes simplex 
encephalitis (HSE), the most common form of sporadic viral encephalitis in the western 
world, which is observed during primary infection with herpes simplex virus-1 (HSV-1). HSE 
is known since 1941, and has been rarely seen in familial form. Children who develop HSE 
upon HSV-1 infection are not particularly susceptible to other infections, and children with 
other PIDs are not more susceptible to HSE (8) , thus a genetic basis for the disease was 
not suspected. The first genetic etiology of HSE, recessive mutations in UNC93B1, was 
described in 2006 (175) . Since then, six other genetic causes of HSE have been described 
(110, 167, 176–179) : autosomal dominant and autosomal recessive TLR3 deficiency, 
autosomal dominant TBK1 deficiency, autosomal dominant TRAF3 deficiency, autosomal 
dominant and autosomal recessive TRIF deficiency, and autosomal dominant IRF3 
deficiency. Because the disease is not systematically observed in individuals carrying the 
risk genotypes, susceptibility to HSE can be described as an example of monogenic but 
not fully penetrant susceptibility to infection.  
Based on these examples and on similar findings that could not be explained using the 
previously accepted model, Alcaïs et al. proposed a more comprehensive model for the 
genetic architecture of infectious diseases in 2010 (Figure 3) (180) . In this model, age and 
fatality rate are considered important co-factors in deciphering the genetic architecture of 
infectious diseases. The monogenic component of the spectrum provides an explanation 
for the occurrence of life-threatening primary infections, which happen mostly in childhood, 
whereas polygenic/complex predisposition is more likely to explain secondary infections 
and infection reactivations, which occur mostly in older patients. Additional support for this 
model comes from a recent study by Brodin et al., who investigated 204 immunological 
parameters in 210 healthy twins and showed that many of them become more variable with 
age, suggesting that the cumulative influence of environmental exposure alters the role of 
human genetics in susceptibility to infectious diseases in older patients (181) .  
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Any infectious disease is the result of the interplay between host, pathogen and the 
environment. The evolutionary arm race between host and pathogen is a great force that 
shapes both host and pathogen genomes (182) . As discussed above, the clinical outcome 
of infections is influenced by variation in the human genome. On the other hand, genetic 
variation in pathogen genomes can also affect disease severity and clinical outcome. The 
power of pathogen genomics studies to transform our understanding of infectious disease 
became clear with the full genome sequencing of the first pathogen, Haemophilus 
influenzae, in 1995 (183) . Since then, pathogen genomics studies have been used to 
study drug resistance, transmission patterns, analysis of disease outbreaks, clinical 
diagnosis and pathogen virulence (184) . In a controversial study in 2012, Burke et al. used 
site-directed mutagenesis to mutate influenza A (H5N1) virus and showed that the virus 
can acquire mutations that greatly increase pathogenicity by enabling airborne 
transmission of the virus between mammals (185) . Multiple studies of influenza A (H1N1) 
virus reported association between mutations in haemagglutinin (HA), non-structural 
protein 1 (NS1) and polymerase basic protein 2 (PB2) and viral virulence (186) . Mutations 
in genotypes C and D of hepatitis B virus (HBV) have been shown to be associated with 
liver cirrhosis and progression to hepatocellular carcinoma, which are the most severe 
long-term complications of HBV infection (187) . These findings highlight the importance of 
including pathogen genomics in the study of human infections. Yet, most genomic studies 
of infectious diseases are conducted from the perspective of the host because the human 
genome is relatively conserved from generation to generation. Conversely, most pathogen 
genomes exhibit relatively high variability, making it challenging to discern mutations that 
have a modulating impact on host interaction and virulence from other neutral mutations 
(188) . With widespread access to HTS technologies, it is now possible to sequence 
? ???
viruses, bacteria, fungi or parasites isolated from each infected host and to look for 
pathogen genetic factors that can affect virulence. The result of such studies will help to get 
a more comprehensive picture of infectious disease pathogenesis and will pave the way for 
development of new preventive and therapeutic measures.  
??? ??????????????????????????
Infectious diseases are among the leading causes of human morbidity and mortality and 
the burden of infectious disorders is the greatest in the pediatric population. As described 
above, recent findings support the idea of a monogenic but non-Mendelian basis for many 
infectious diseases of childhood, and incomplete penetrance seems to be the rule rather 
than the exception. One strategy to increase the efficiency of gene discovery is to 
sequence individuals with the most dramatic clinical presentation, i.e. at the extreme of the 
phenotype distribution. The promise of this approach comes from the fact that variants of 
large effect sizes are under strong purifying selection and thus are found at low frequencies 
in the general population. Accordingly, for each trait with a normal distribution of phenotypic 
outcome in a population, individuals that are part of the tail of the distribution are more 
likely to carry variants of profound effect. Therefore, it is possible to design relatively small 
sequencing studies by focusing on individuals with extreme phenotypes, who are most 
likely to be informative genetically. Life-threatening susceptibility to individual pathogens in 
pediatric population is a rare, if not extremely rare, condition and extreme phenotype 
sampling is particularly beneficial to find the genetic etiology of these disorders. 
In the next two chapters of this work, I present two host genomic studies, in which we used 
exome sequencing, bioinformatic analysis and functional follow-up to explore the genetic 
basis of extreme susceptibility to common infections in the pediatric population. The first is 
severe sepsis due to Pseudomonas aeruginosa (P. aeruginosa), an opportunistic 
bacterium that is found in abundance in soil, water and air, and rarely causes clinical 
symptoms in healthy individuals. However, in rare cases, it can cause bacteraemia and 
sepsis in previously healthy individuals, resulting in a high mortality rate. The second is 
severe lower respiratory tract infection due to respiratory syncytial virus (RSV). RSV is the 
most common viral respiratory infection in children, and usually causes only mild and self-
limiting symptoms in healthy individuals. In the fourth chapter, I describe a viral genomic 
study, in which we used high-throughput sequencing to compare the genetic variability of 
two RSV strains extracted from nasopharyngeal aspirates (NPAs) of patients with extreme 
susceptibility to RSV with genomic variation of RSV strains extracted from patients with 
milder symptoms. 
The global aim of this research is to identify human and pathogen genetic factors that 
contribute to inter-individual differences in susceptibility to P. aeruginosa and RSV. An 
improved understanding of the molecular basis of these differences could provide 
invaluable insight into host-pathogen interactions and disease pathogenesis. 
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Pseudomonas aeruginosa (P. aeruginosa) is an aerobic gram-negative bacterium 
commonly found in soil, water and plants. This opportunistic pathogen causes invasive 
infections in immunosuppressed and hospitalized patients, and represents a major cause 
of healthcare-related infections. Sepsis due to community-acquired P. aeruginosa is 
extremely rare in apparently healthy children, and carries very high mortality (1, 2). Few 
case reports have described a range of primary immunodeficiencies (PID) in children with 
P. aeruginosa sepsis (3, 4). While genetic alterations leading to PID are kept at very low 
frequency in the general population through negative selection, these variants may be 
found at higher frequency in children presenting with severe infections in the absence of 
known comorbidities (5). Here, we used exome sequencing to identify genetic variants 
causing PIDs in previously healthy children with P. aeruginosa sepsis.  
??? ????????????? ???????
????? ?????????
Children below 60 month-old with community-acquired P. aeruginosa bloodstream sepsis 
(6) were eligible. Patients with existing comorbid conditions (prematurity, congenital 
malformations, previous surgery, immunosuppression, known immunodeficiency, chronic 
diseases) were excluded. The ethics committees of participating centers approved the 
study. Written informed consent from parents was obtained. Patients were recruited 
prospectively, and retrospectively in hospital databases and infectious diseases networks. 
Whenever possible, DNA was also collected from the parents.  
????? ????????????????????????????????????
Human genomic DNA was extracted from whole blood (N=8) or from fibroblasts cultured 
from frozen skin biopsy, frozen lymphatic tissue, or paraffin-fixed histology slides in one 
patient each. Exome sequencing libraries were prepared using Agilent SureSelect (V5 
spanning 50.4 Mb). Cluster generation was performed using the Illumina TruSeq PE 
Cluster Kit v5 reagents. The resulting libraries were sequenced as 100 basepair long, 
paired-end reads on Illumina HiSeq 2500 using TruSeq SBS Kit v5 reagents. 
? ???
????? ??????????????????????????????????????????????????????????????
Raw sequencing reads were processed using CASAVA v1.82. Reads were aligned to 
human reference genome hg19 using BWA v0.6.2 (7). PCR duplicates were removed using 
Picard. Single nucleotide variants (SNVs) and small insertion and deletions (Indels) were 
called by the HaplotypeCaller in Genome Analysis Toolkit v3.1-1 using a multi-sample 
approach. We used SnpEff (8) to predict the functional impact of variants. The presence of 
a functionally relevant variant was confirmed using custom Taqman® genotyping assays. 
????? ????????????????????????????????????????????
We restricted analyses to nonsynonymous exonic variants with a minor allele frequency 
(MAF) < 1%. For parent-child trios, we analysed each family separately assuming multiple 
inheritance models (autosomal recessive, autosomal dominant, X-linked recessive, 
compound heterozygous recessive). Only variants with at least 10X coverage in both 
parents and the offspring were included in the de novo analysis. For individual patients, we 
searched for rare, nonsynonymous variants assuming autosomal recessive, or X-linked 
recessive inheritance. We did not consider a mutation as potentially causal if it was present 
in the Exome Aggregation Consortium database (ExAC, http://exac.broadinstitute.org) or in 
a set of 533 in-house control exomes in the same zygosity form (i.e. heterozygous or 
homozygous) as in our patients. In addition, we ran a targeted search for rare, 
nonsynonymous variants in a list of 251 known PID genes (9).  
????? ????????????????????????????????????
We used the Database for Annotation, Visualization and Integrated Discovery  (10) 
(DAVID, https://david.ncifcrf.gov/home.jsp) v6.7 with default options and highest 
classification stringency for functional annotation clustering of PID genes carrying rare, 
nonsynonymous variants. We used hypergeometric test for assessing the significance of 
the gene enrichment result. 
??? ????????
????? ???????????????????????????????????
We identified 11 previously healthy children with community-acquired P. aeruginosa 
bacteremia from whom DNA could be obtained. The presenting age ranged from 6 months 
to 4 years, and 7/11 (64%) of patients were male. One surviving patient presented with 
acute abdomen, and P. aeruginosa bacteraemia was thought to result from intra-abdominal 
perforation. Another surviving patient was diagnosed with urosepsis and P. aeruginosa 
grew in urine and blood. Post-mortem examination reports were available in seven cases. 
In four, P. aeruginosa grew in high quantities from nasal and oral mucosal swabs, tracheal 
secretions, and lungs in one case patient presented with ecthyma gangraenosum (Table 
2.1, Figure 2.1).  
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The mean coverage was 66x and 96% of target bases achieved at least 10x coverage. 
115,604 SNVs and 10,814 indels passed GATK quality control: 28,795 synonymous 
variants, 28,284 nonsynonymous variants, 713 in-frame indels, 660 frame-shift indels, 283 
stop-gained and 151 splice-site variants (Tables 2.2-4.4).  
????????????????????????? ???????
????????????????
 
Sample 
PF 
unique 
reads 
PF unique 
reads 
aligned 
Off-bait
(%) 
Mean 
bait 
coverage 
At least 2X 
coverage (%) 
At least 30X 
coverage 
(%) 
P101 97.25 96.66 0.23 65.71 99.39 80.6249 
P102 96.90 96.54 0.24 59.08 99.26 77.17 
P103 96.39 95.99 0.26 62.26 99.39 78.68 
P201 97.00 94.46 0.25 50.43 99.15 67.86 
P202 98.94 96.55 0.25 17.97 97.55 15.88 
P203 97.18 96.52 0.25 72.83 99.37 82.47 
P301 97.77 96.40 0.25 58.37 99.24 76.44 
P302 96.89 96.59 0.25 52.85 99.22 72.69 
P303 97.68 96.73 0.25 33.83 98.99 49.09 
P401 96.59 96.25 0.25 53.94 99.30 73.01 
P402 97.91 96.55 0.26 27.91 98.70 38.48 
P403 96.76 96.38 0.25 74.31 99.41 84.49 
? ???
P501 93.31 96.23 0.25 135.58 99.54 95.47 
P601 95.24 95.83 0.26 142.89 99.44 95.83 
P701 95.80 97.65 0.20 76.20 99.51 88.79 
P801 95.76 97.54 0.21 64.23 99.46 82.94 
P901 97.77 98.34 0.18 71.25 99.47 86.70 
P902 97.87 98.28 0.19 79.31 99.48 89.13 
P903 97.93 98.31 0.18 78.05 99.38 89.05 
P1001 62.75 97.47 0.20 50.54 99.41 77.05 
P1002 97.99 98.30 0.19 70.82 99.38 86.75 
P1003 97.38 98.23 0.19 74.50 99.49 87.56 
P1101 98.31 98.21 0.20 68.41 99.42 84.36 
P1102 98.40 98.32 0.20 58.27 99.34 79.93 
P1103 98.51 98.27 0.20 64.83 99.46 83.36 
?
???????????????????????????????? ???????
????????????????????????????????????????????? ???????????????
 
Sample 
 
nVariant 
Loci 
 
nNovel 
Variant 
 
nSNPs 
 
nIndels 
 
nHom 
 
nTi 
 
nTv 
P101 43273 592 39141 3313 16449 28370 10761 
P102 42953 558 38934 3251 16726 28258 10666 
P103 43465 606 39371 3298 16520 28528 10837 
P201 42759 589 38831 3196 16846 28191 10628 
P202 40085 491 36680 2884 16663 26676 9997 
P203 42646 569 38688 3165 16792 27949 10733 
P301 43017 588 39016 3232 16606 28251 10755 
P302 43347 599 39318 3256 16660 28443 10865 
P303 41937 531 38170 3079 16791 27645 10515 
P401 43589 706 39495 3302 17037 28579 10905 
P402 42590 664 38770 3165 16636 28047 10711 
P403 43739 725 39572 3354 17205 28661 10897 
P501 44179 1090 39876 3441 17331 28761 11101 
P601 52709 876 47759 3950 18160 34522 13214 
P701 43468 603 39305 3336 16919 28401 10889 
P801 43100 602 38985 3319 16506 28178 10792 
P901 43040 939 39082 3289 18359 28282 10780 
P902 42986 907 38957 3325 18221 28210 10726 
P903 43674 940 39612 3369 18418 28673 10927 
P1001 44467 1215 39340 4213 16249 28491 10830 
P1002 43468 696 39350 3423 16353 28488 10845 
P1003 42907 648 38912 3346 16586 28096 10806 
? ???
P1101 43093 941 39077 3333 18776 28175 10885 
P1102 43204 858 39228 3294 18578 28372 10837 
P1103 43188 903 39194 3305 18420 28237 10937 
??
 
????????????????????????????? ???????
Sample frame_ 
shift 
stop_ 
gained 
stop_ 
lost 
start_ 
lost 
splice_ 
site 
missense 
 
inframe synonymous 
 
    UTR 
P101 227 65 23 16 65 8674 182 9718 1999 
P102 220 60 22 18 58 8511 185 9686 1988 
P103 213 59 24 15 71 8809 171 9710 1986 
P201 204 54 27 12 62 8597 181 9684 1914 
P202 191 45 24 14 57 8184 177 9325 1855 
P203 215 63 24 9 58 8534 175 9551 1915 
P301 209 62 22 15 52 8700 190 9685 1937 
P302 209 59 20 14 52 8633 188 9763 1928 
P303 195 51 25 12 52 8560 177 9525 1936 
P401 210 59 26 18 61 8658 206 9862 2015 
P402 220 50 26 18 62 8637 201 9862 1955 
P403 218 51 25 16 60 8636 204 9856 2015 
P501 231 57 24 12 62 8668 221 9960 1988 
P601 236 63 26 19 67 10229 217 12000 2390 
P701 206 54 23 12 65 8635 217 9713 1982 
P801 210 54 25 16 64 8533 201 9770 2016 
P901 210 62 25 20 70 8627 208 9809 1954 
P902 240 66 24 20 64 8579 193 9688 1958 
P903 232 62 24 15 72 8634 214 9903 1992 
P1001 243 47 26 15 62 8644 258 9882 2070 
P1002 234 56 24 19 55 8722 230 9830 1978 
P1003 218 59 27 12 64 8495 209 9779 2002 
P1101 231 64 22 21 63 8580 194 9700 1998 
P1102 221 64 22 21 63 8558 197 9742 2020 
P1103 229 50 22 17 65 8536 182 9796 1965 
 
????? ?????????????????
Thirty-nine rare nonsynonymous variants (MAF < 1%) were observed in the 11 patients 
among which 12 were never seen in the same zygosity form (i.e. heterozygous or 
homozygous) in ExAC (Table 2.5). In addition to the above 39 variants, we identified 76 
rare (MAF < 1%) nonsynonymous variants in 60 known PID genes (Table 2.6). Functional 
classification of these 60 genes using DAVID?highlighted the complement pathway as the 
most enriched cluster: 13 of the 29 complement pathway genes present in the list of 251 
known PID genes carried at least one rare, nonsynonymous coding variant (DAVID 
enrichment score: 12.57, hypergeometric probability: 0.0058). 
? ???
In one patient with fatal septic shock, we identified a novel single-base insertion on, the X 
chromosome (C>CT at position 100617191) leading to a frame-shift in the Bruton 
agammaglobulinemia Tyrosine Kinase (BTK) gene, BTK plays a crucial role in B-cell 
development. Postmortem serological testing confirmed absence of immunoglobulins, 
consistent with BTK loss-of-function (IgG <1.3g/L; IgA <0.2g/L; IgM <0.2g/L). 
?
???????????????????????????????????????
???????????????????????????????????????????????????????????????????????????????????????????????????????????
????????????????????? 
Inheritance  Chromosome Position Gene Effect ExAC 
MAF (%) 
Autosomal 
recessive 
7 142562052 EPHB6 INSERT 0 
20 31393172 DNMT3B DELETE 0 
de novo 
19 41025445 SPTBN4 MISSENSE 0 
13 112721975 SOX1 MISSTART 0 
 
X-linked 
X 27998602 DCAF8L1 MISSENSE 1.14E-03 
X 100617192 BTK FRAMESHIFT 0 
X 9864517 SHROOM2 MISSENSE 0 
X 53575033 HUWE1 MISSENSE 0 
X 70824419 ACRC MISSENSE 0 
X 68382133 PJA1 MISSENSE 0 
X 101097713 NXF5 DONOR 0 
X 109561080 AMMECR1 MISSENSE 0 
?
?
????????????????????????????????????????????????????
???????????????????????????????? ????????????????????????????????
Chr. 
 
Position 
 
Effect 
 
Gene 
 
MAF (%) 
nHom in 
ExAC 
nHet in 
ExAC 
1 207646266 MISSENSE CR2 3.30E-03 0 4 
1 949431 MISSENSE ISG15 4.17E-03 0 5 
1 235896980 MISSENSE LYST 0.02 0 27 
1 154247666 MISSENSE HAX1 0.03 0 31 
1 22965341 MISSENSE C1QA 0.04 0 13 
1 11094908 MISSENSE MASP2 0.08 1 95 
1 183536358 MISSENSE NCF2 0.23 2 273 
1 949422 MISSENSE ISG15 0.16 3 192 
1 151316324 MISSENSE RFX5 0.88 10 1045 
1 207925595 MISSENSE CD46 0.5 11 585 
1 196684855 MISSENSE CFH 0.5 17 577 
? ???
1 196799796 MISSENSE* CFHR1 0.14 41 74 
1 196715063 MISSENSE CFH 0.97 58 1056 
2 231036831 MISSENSE SP110 4.12E-03 0 5 
2 47277182 MISSENSE TTC7A 0.2 1 245 
2 47273468 MISSENSE TTC7A 0.21 2 248 
3 196198925 MISSENSE RNF168 0.2 6 232 
4 151242409 MISSENSE LRBA 0.46 2 560 
4 110667485 MISSENSE CFI 0.34 5 405 
4 187004767 MISSENSE TLR3 0.3 7 339 
5 39342214 NONSENSE C9 0.1 0 120 
5 77334907 MISSENSE AP3B1 0.08 0 97 
5 1268697 MISSENSE TERT 0.09 0 113 
5 147475388 MISSENSE SPINK5 0.65 3 779 
5 35876300 MISSENSE IL7R 0.24 5 283 
5 41155088 MISSENSE C6 0.69 8 823 
5 41155088 MISSENSE C6 0.69 8 823 
5 158750329 MISSENSE IL12B 0.65 12 763 
5 40945397 MISSENSE C7 0.95 35 1069 
6 31915584 MISSENSE CFB 0.1 0 116 
6 32798457 MISSENSE TAP2 0.49 2 569 
6 137540425 MISSENSE IFNGR1 0.14 4 156 
6 32800427 MISSENSE TAP2 0.61 8 697 
8 100844596 DISRUPT VPS13B 0.43 0 330 
8 100654621 MISSENSE VPS13B 0.02 0 20 
8 100861113 MISSENSE VPS13B 0.06 1 74 
8 48733399 MISSENSE PRKDC 0.09 2 108 
8 90982691 MISSENSE NBN 0.26 6 299 
8 42177163 MISSENSE IKBKB 0.89 59 958 
9 340168 MISSENSE DOCK8 0 0 0 
9 139264888 MISSENSE CARD9 0.35 2 406 
9 139840153 MISSENSE C8G 0.46 6 262 
9 123751873 MISSENSE C5 0.61 20 691 
9 123737145 MISSENSE C5 0.91 47 1012 
10 97983635 MISSENSE BLNK 0.55 10 645 
10 73103969 MISSENSE SLC29A3 0.54 19 617 
10 6063567 MISSENSE IL2RA 0.88 51 969 
11 118898444 MISSENSE SLC37A4 0 0 0 
11 4104647 MISSENSE STIM1 8.25E-04 0 1 
11 108117787 MISSENSE ATM 0.13 0 155 
? ???
11 6637588 MISSENSE TPP1 0.18 1 216 
11 2407334 MISSENSE CD81 0.56 1 100 
11 108119823 MISSENSE ATM 0.22 2 260 
11 108129778 MISSENSE ATM 0.21 5 247 
11 108123551 MISSENSE ATM 0.29 5 335 
11 108098576 MISSENSE ATM 0.74 5 883 
11 108138003 MISSENSE ATM 0.91 13 1084 
12 122064747 MISSENSE ORAI1 0 0 0 
12 110017618 MISSENSE MVK 0.07 0 87 
12 133263886 MISSENSE POLE 0.14 0 21 
12 110034347 MISSENSE* MVK 0.13 6 141 
15 91337505 MISSENSE BLM 0.1 1 119 
15 91295110 MISSENSE* BLM 0.86 43 956 
16 27460420 MISSENSE IL21R 0.03 0 34 
16 50745960 MISSENSE NOD2 0.03 0 41 
16 81957106 MISSENSE PLCG2 0.13 2 154 
17 73826517 MISSENSE UNC13D 2.25E-03 0 1 
17 26875685 MISSENSE UNC119 0.01 1 11 
17 76120792 MISSENSE TMC6 0.65 7 351 
19 18170874 MISSENSE IL12RB1 0.17 1 204 
20 31393172 DELETE* DNMT3B 0 0 0 
20 62324328 MISSENSE RTEL1 0.98 61 1052 
22 36662063 MISSENSE APOL1 0.01 0 18 
22 31007023 MISSENSE TCN2 0.27 6 314 
X 100617192 FRAMESHIFT BTK* 0 0 0 
X 77150892 MISSENSE MAGT1 0.29 106 120 
?
A novel homozygous deletion spanning 6 base pairs on chromosome 20 (ACTCGAG>A at 
position 31393171) was observed in a two-year-old boy with consanguineous parents 
leading to an in-frame deletion in a conserved region of the catalytic domain of the 
DNMT3B gene. Previously described missense mutations in the same protein domain are 
known to cause immunodeficiency-centromeric instability-facial anomalies (ICF) syndrome 
(11), a rare disease characterized by variable immunodeficiency and recurrent infections 
with mild facial abnormalities. The fatal septicaemia was preceeded by mild varicella and 
the patient had a history of recurrent mild respiratory and ENT infections that had been 
attributed to poor health conditions. The patient had normal T and B cell subsets but 
reduced immunoglobulin levels, consistent with ICF syndrome: IgG 0.16g/L (4.22-11.9); IgA 
<0.06g/L (0.2-1.58); IgM 0.05g/L (0.48-1.9).  
We also observed a known, very rare (MAF=0.00015 in ExAC) heterozygous stop-gain 
variant in the complement C9 gene, on chromosome 5 (G>T at position 39342214) in a 
???
male patient with non-fatal Pseudomonas septicaemia and recurrent parainfectious 
neutropenia. However, complement reconstitution assay with classical or terminal pathway 
protein (C1 to C9) showed normal lytic activity (Figure 2.2), suggesting that this variant is 
unlikely to be causally related to increased susceptibility to P. aeruginosa. 
??????????????????????????????????
????????????? ????????????????????????????????????????????????????????????????????????????????????????
??? ??????????????????????????
While mortality due to bacterial sepsis has decreased over the past decade, one out of 
three pediatric sepsis deaths occur in children without major comorbidities (12). Invasive 
infections in children in whom immunodeficiency had not been previously suspected may 
represent the first manifestation of a PID. However, very little is known about the 
prevalence of PIDs in children presenting with bacterial sepsis. We used exome 
sequencing to explore the genetic cause of susceptibility to P. aeruginosa in a selected 
group of previously apparently healthy children with community-acquired P. aeruginosa 
septicemia. We identified PIDs listed in the 2014 International Classification of primary 
immunodeficiencies in two cases: X-linked agammaglobulinemia due to a novel BTK 
mutation and ICF immunodeficiency syndrome due to a novel DNMT3B mutation. In 
addition, we observed 76 rare missense variants in known PID genes, in particular within 
the complement pathway. Functional testing of a surviving patient with a heterozygous 
protein-truncating variant in C9 revealed normal lytic activity, demonstrating the need for 
strict validation of potential causal mutations, even in genes with a plausible biological link 
to the study phenotype.  
Previous case reports describing PIDs such as Wiskott-Aldrich syndrome, X-linked 
agammaglobulinemia, cyclic neutropenia and IRAK-4/MyD-88 deficiency (2, 3, 13) in P. 
? ???
aeruginosa sepsis were based on conventional candidate-based immunologic testing. In 
view of the genetic heterogeneity in human susceptibility to sepsis, classic PID screening 
may fail to identify new mutations in known PID genes and makes no attempt at expanding 
our understanding of the genetic causes of the disease, with potentially devastating 
consequences for survivors, undiagnosed siblings and their families.  
In our cohort, defects in known PID genes were found in 25% of fatal cases. While non-
genetic factors including pathogen variability and non-genetic causes of neutropenia may 
be responsible for the remaining cases, we cannot rule out that mutations in genes not 
previously associated with PID are at least partially involved. Sequencing of additional 
family members, sequencing of more cases with the same phenotype and functional 
characterization of new candidate genes and variants will be required to investigate these 
genetic factors. 
In conclusion, this study provides proof-of-concept that exome sequencing allows the 
identification of rare, deleterious human genetic variants responsible for fulminant sepsis in 
children in whom immunodeficiency had not been previously suspected. We were able to 
diagnose PID in several cases, with a significant impact on affected families. Given the 
decreasing cost of exome sequencing, we propose to consider it as a diagnostic procedure 
for apparently healthy children presenting with unusually severe or fatal sepsis. 
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Viral respiratory tract infections are the most common pediatric infections worldwide. 
During early childhood, virtually every individual goes through several episodes of viral 
respiratory infections, which are usually mild and self-limiting. Yet, serious disease leads to 
the hospitalization of about 1% of individuals in each birth cohort. In-hospital mortality rates 
are limited to 0.5% with intensive care support, still these infections account for 21% of 
childhood mortality worldwide (1, 2). The main viral pathogens causing lower respiratory 
tract infections are human respiratory syncytial virus (RSV), enteroviruses (including 
rhinoviruses), adenoviruses, metapneumovirus, influenza and parainfluenza viruses, with 
RSV being responsible for the majority of the hospitalized cases (3, 4). A number of risk 
factors including socio-economic and environmental influences (e.g. malnutrition and 
smoking parents), male gender, preterm birth, chronic diseases and immunosuppression 
are associated with more severe disease (5, 6). Yet, approximately 1 out of 1000 children 
without any known risk factor or co-morbidity will require intensive care support due to life-
threatening manifestations of common viral respiratory infections. This “silent epidemic” of 
potentially lethal infections before reproductive age remains largely unexplained. In the 
absence of established differences in pathogen virulence, we hypothesized that human 
genetic variation could be involved. We therefore combined exome and transcriptome 
sequencing and in vitro functional testing to identify and characterize potentially causal 
genetic variants in carefully selected clinical cases. 
??? ????????????? ???????
????? ????????????????????????????????????????????
Previously healthy children suffering from severe lower respiratory tract infections were 
recruited between 1.12.2010 and 30.09.2013 in five specialized Pediatric Intensive Care 
Units (PICU) in Australia and Switzerland (Australia: Mater Children’s Hospital, and Royal 
Children’s Hospital, Brisbane; Switzerland: Children’s Hospital Lucerne, Lucerne; Centre 
Hospitalier Universitaire Vaudois, Lausanne; Département de l’Enfant et de l’Adolescent, 
Hospital Universitaire de Genève, Geneva). The study was approved by the institutional 
Human Research Ethics Committees. Informed consent was obtained from parents or legal 
guardians.  
? ???
Children aged below 4 years that were admitted to PICU due to a severe respiratory 
infection of proven or presumed viral origin, and who required respiratory support were 
eligible. Exclusion criteria were the presence of any significant underlying disease or 
comorbidity, including prematurity, congenital cardiac disease, chronic lung disease 
including cystic fibrosis, sickle cell disease, hepatic, renal, or neurologic chronic conditions, 
solid and haematological malignancies and known PID. Respiratory support was defined 
as non-invasive modes of ventilation (NIV) including high-flow nasal cannulae (HFNC) and 
continuous or bilevel positive airway pressure (CPAP and BiPAP), vs. invasive (IV) 
ventilation including conventional and high-frequency oscillation ventilation (HFOV). The 
following demographic and clinical information was collected for each recruited subject: 
age, gender, weight, ethnicity, type of ventilation needed, length of ventilation in days, 
clinical outcome, microbiological diagnostic procedures and results including rapid test for 
RSV and influenza, viral PCR, and viral cultures. The Pediatric Index of Mortality 2 (PIM2) 
was used to assess patient illness severity at PICU admission. 
Parents were approached by the study investigator immediately following PICU admission, 
and, when consent was available, blood and respiratory samples were obtained. For each 
study subject a nasopharyngeal aspirate, 1ml EDTA blood in vacutainer tubes and 2.5ml 
blood in PAXgene blood RNA tubes (catalog number 762165; PreAnalytiX, Hombrechtikon, 
Switzerland) were collected. Samples were immediately frozen at -70 degrees Celsius until 
shipment, and then analyzed in batch. 
????? ?????????????????????????????????
Samples were extracted individually (100ul sample from nasopharyngeal aspirate + 300ul 
PBS) using the NucliSens Easymag© (bioMérieux, Geneva, Switzerland) according to the 
manufacturer's instructions. Respiratory viruses screening was performed using FTD 
Respiratory pathogens 21 assay (Fast-track Diagnostics) on a Viia7 instrument (Applied 
biosystems, Switzerland). 
????? ???????????????????????????????
Genomic DNA was extracted from whole blood (catalog number 51104; QIAGEN, 
Hombrechtikon, Switzerland). Exome sequencing libraries were prepared with 2 μg to 3 μg 
of genomic DNA using Agilent SureSelect reagents (catalog numbers 5190-4627, 5190-
4631, 5190-6208 and G9611A; Agilent Technologies, Santa Clara, USA) according to the 
protocols supplied by the manufacturer. Cluster generation was performed using the 
Illumina TruSeq PE Cluster Kit v3 reagents. The resulting libraries were sequenced as 100-
nucleotide, paired-end reads on Illumina HiSeq 2000 or HiSeq 2500 using TruSeq SBS Kit 
v3 reagents. Sequencing was done at the Lausanne Genomic Technology Facility. Raw 
sequencing reads were processed using the Illumina Pipeline Software version 1.82. 
Purified filtered reads were aligned to human reference genome hg19 using Burrow-
Wheeler Aligner version 0.6.2 (BWA) (7) (supplementary table 2). PCR duplicates were 
removed using Picard (http://picard.sourceforge.net/).  
? ???
????? ????????????????
We used Genome Analysis Toolkit (GATK) (8, 9) version 3.1-1, Platypus  (10) version 
0.7.9.1 and SAMtools  (11) version 0.1.19 to call single nucleotide variants (SNVs) and 
small insertion and deletions (Indels) from duplicate-marked bam files. With GATK we used 
HaplotypeCaller for multi-sample variant calling. We followed GATK best practice to call 
the variants (https://www.broadinstitute.org/gatk/guide/best-practices?bpm=DNAseq); 
variants that didn’t pass GATK filtering were filtered out. With Platypus we used 
callVariants for multi-sample variant calling and variants that didn’t pass Platypus filtering 
criteria were filtered out. With SAMtools we used mpileup default options for multi-sample 
variant calling followed by bcftools view to generate the vcf file, variants with quality score 
below 30 were filtered out. After variant calling, variants that were present in the 
intersection of the three variant callers with missingness below 5% were used for further 
annotation and down stream analysis.  
????? ???????????????????
We used SnpEff  (12) version 4.1B to predict the functional impact of variants, and notably 
to identify putative loss of function variants (LoFs).  We defined these categories of 
variantions as LoF: stop-gain SNVs, splice site disrupting SNVs and frame shift indels in 
the first 95% of coding region or larger deletions removing either the first exon or more than 
50% of the protein-coding sequence of the affected transcript. We further enriched for LoFs 
that are likely to abolish protein structure by including only LoFs that affected all the coding 
transcripts of a gene.  
????? ?????????????????????????????
Total RNA was extracted from 2.5 ul of whole blood using PAXgene blood RNA kit (catalog 
number 762174; PreAnalytiX, Hombrechtikon, Switzerland). Libraries were prepared using 
the Illumina TruSeq Stranded mRNA (Ribo-Zero Globin) reagents (Catalog number RS-
122-2501; Illumina; San Diego, USA) according to the protocol supplied by the 
manufacturer and using 400ng of total RNA. Cluster generation was performed with the 
Illumina TruSeq PE Cluster Kit v3 reagents. The resulting stranded libraries were 
sequenced as 100-nucleotide, paired-end reads on the Illumina HiSeq 2000 using TruSeq 
SBS Kit v3 reagents. The raw sequencing reads were processed using the Illumina 
Pipeline Software version 1.82. Purified filtered reads were aligned to the human reference 
genome hg19, using STAR (13) version 2.3.0e and the Gencode annotation (14) version 
19. 
????? ??????????
β-IFN-fl-lucter contains the firefly luciferase gene driven by the human IFNβ promoter as 
described previously (15). pTK-rl-lucter contains the Renilla luciferase gene (PROMEGA) 
driven by the herpes simplex virus TK promoter. pEBS-tom encodes a red fluorescent 
protein.   
pcDNA3.1(+) containing wild-type (wt) IFIH1 was constructed by PCR amplification on 
pEF-BOS-IFIH1 with sense primer that introduced a BamHI site and flag sequence at the 
? ???
N-terminus and with the antisense primer that introduced a XhoI site at the C-terminus of 
IFIH1. The PCR products were inserted into pcDNA3.1(+) after digestion with BamHI and 
XhoI.?
pcDNA3.1(+) containing mutant IFIH1 lacking exon 14 (IFIH1-Δ14), was constructed using 
a fusion PCR strategy. First, pEF-BOS-IFIH1 was amplified by PCR with a sense primer 
that introduced a BamHI site and a HA sequence at the N-terminus of IFIH1 and with the 
antisense primer that inserted the beginning of exon 15 sequence at the end of the exon 
13. Second, pEF-BOS-IFIH1 was amplified by PCR with a sense primer that introduced the 
end of exon 13 sequence at the beginning of exon 15 and with the antisense primer that 
introduced a XhoI site at the C-terminus of IFIH1. The resulting PCR products were mixed 
and amplified by PCR with a sense primer that introduced a BamHI site and a HA 
sequence at the N-terminus and with the antisense primer that introduced a XhoI site at the 
C-terminus of IFIH1. The PCR products were digested with BamHI and XhoI and then 
inserted into pcDNA3.1(+). 
pcDNA3.1(+) containing deletion mutant IFIH1 lacking exon 8 (IFIH1-Δ8), and 
pcDNA3.1(+) containing deletion mutant IFIH1 with a stop-gain mutation in exon 10 (IFIH1-
ΔCTD), were ordered from life technologies plasmid service. 
The inserts of the resulting pcDNA3.1(+) containing IFIH1-wt or mutant plasmids were 
confirmed by sequencing. 
????? ????????????? ? ?????????????????????????????????????????
293T cells and Huh7.5 cells were grown in Dulbecco’s modified Eagle’s medium 
supplemented with 10% fetal bovine serum and 1% Pen/Strep. 100’000 cells were plated 
into 6-well plates and transfected 24 hrs later with 1.5 μg of pβ-IFN-fl-lucter, 0.5 μg of pTK-
rl-lucter and 0.5 μg of pEBS-tom (used as a transfection control), using Gene Juice 
transfection reagent (NOVAGEN). Additionally, cells were transfected with 1 μg of IFIH1 
encoding plasmids. 24 hrs later, Huh7.5 cells (but not 293T cells) were transfected with 
elicitor RNA using TransMessenger transfection reagent (QIAGEN) according to the 
manufacturer’s instructions. 20 hrs later, cells were harvested and cell lysates were used to 
measure firefly and Renilla luciferase activity (dual-luciferase reporter assay system, 
Glomax 20/20 luminometer, PROMEGA).  
Protein expression in the cell lysates was then checked by Western blotting, using the 
following primary antibodies: anti-RIG-I (1:1000) (Alexis ALX-210-932), anti-IFIH1 (1:1000) 
(Alexis ALX-210-935), anti-HA (1:2000) (Enzo Life Sciences ENZ-ABS-118-0500), anti-flag 
(1:1000) (Sigma F1804-1MG). Immunoblot analyses were developed with the following 
secondary antibodies: goat anti-mouse and anti-rabbit IgG horseradish peroxidase 
conjugated whole antibody (1:3000) (Bio-Rad). ImageJ version 1.44p 
(http://imagej.nih.gov/ij/) was used for western blot quantifications. 
 
? ???
????? ????????
Respiratory Syncytial Virus expressing Green Fluorescent Protein (RSV-GFP, obtained 
from Mark peeples (49)) or mCherry (rRSV-mCherry obtained from Jean-François Eléouët  
(50)) stock were amplified in A549 (human alveolar adenocarcinoma cell line) cells. RSV-
GFP stock titers were determined using serial dilutions to infect A549 cells. GFP or 
mCherry expression was measured by flow cytometry on 20’000 cells (i.e. 10% of the 
harvested cells) using BD Accuri C6 Cytometer. Data were analyzed using CFlow Plus 
software (Accuri, version 1.0.264.15). Fluorescence pictures were acquired using Evos FL 
epifluorescence microscope. Recombinant vesicular stomatitis virus expressing Green 
Fluorescent Protein (rVSV-GFP obtained from Jacques Perrault (51)) stock were amplified 
in 293T cells and stock titers were determined using serial dilutions to infect 293T cells. 
GFP expression was measured by flow cytometry on 20’000 cells (i.e. 10% of the 
harvested cells) using BD Accuri C6 Cytometer. Data were analyzed using CFlow Plus 
software (Accuri, version 1.0.264.15). Fluorescence pictures were acquired using Evos FL 
epifluorescence microscope. 
?????? ????????????????????????????????????????????
Transfected 293T cells were incubated for 30 minutes at 37°C in methionine-free, cysteine-
free and FCS-free DMEM. 100 μCi/ml of 35S-methionine + 35S-cysteine labelling mix 
(HARTMAN Analytic) was added and cells were incubated at 37°C for 30 minutes. The 
chase (0, 2, 4, and 8 hours) was performed at 37°C in DMEM supplemented with 
unlabelled methionine and cysteine (10mM). Cell lysates were loaded on 7.5% acrylamide 
gels, transferred to a PVDF membrane and exposed to autoradiography. Results were 
revealed in a phosphorimager (Typhoon, GE Healthcare Life Sciences) and quantified with 
ImageQuantTL software (GE Healthcare Life Sciences).  
?????? ?????????????????????????????
IFIH1 inserts cloned into pcDNA3.1(+) were inserted into pET28-His10Smt3 backbone. 
pET28-His10Smt3-IFIH1 wt or ΔCTD plasmids were transformed into E. coli BL21. 
Cultures (500 ml) derived from single transformants were grown at 37°C in LB medium 
containing 50 μg/ml kanamycin to an A600 of 0.6. The cultures were adjusted to 0.2 mM 
IPTG and 2% ethanol and further incubated for 20 hours at 17°C. Cells were harvested by 
centrifugation and recombinant RIG-I protein was purified from bacteria as previously 
described (8). Protein concentration was determined using the Bio-Rad dye binding method 
with BSA as the standard. 
?????? ?????????????????????????????????
Increasing amounts of polyI:C were incubated with 200 nM of purified recombinant IFIH1, 
[(Isqb) γ-32P] ATP (Hartmann Analytic) in a final volume of 15 μl (50 mM Tris acetate pH 6, 
5 mM DTT, 1.5 mM MgCl2) for 15 minutes at 37°C. Reactions were then stopped with 1 
mM formic acid and 2.5 μl of each reaction were spotted onto TLC PEI Cellulose F plates 
(MERCK 1.05579.0001) and applied to a migration buffer (LiCl 0.5 M and formic acid 1 N) 
to separate released 32PO4 and non hydrolyzed ATP. 
32PO4 release was measured in a 
phosphorimager (Typhoon, GE Healthcare Life Sciences) and quantified with 
? ???
ImageQuantTL software (GE Healthcare Life Sciences). ATPase data were processed as 
follow: for each sample, the ratio free 32PO4/non hydrolyzed ATP was calculated (and 
reported to the final ATP concentration in the reaction); fold increases were obtained by 
normalizing the calculated ATPase activity to the ATPase activity of the protein alone 
(control without RNA). 
?????? ?????????????????????????????? ???????????????????????
The 293T cells line were cultured in Dulbecco's modified Eagle's medium supplemented 
with 10% fetal calf serum. All recombinant lentiviruses were produced by transient 
transfection of 293T cells according to the following protocol. 5 x 106 293 cells were plated 
in 10 cm PD and cotransfected with 15 μg of a plasmid vector (pLV.CMV.IFIH1.IRES-GFP 
and pLV-U6-empty-PGK-GFP), 10 μg of psPAX2 and 5 μg of pMD2G-VSVG by calcium 
phosphate precipitation. After 8 hours, medium was changed and recombinant lentiviruses 
vectors were harvested 24 hours later. Huh 7.5 cell lines, platted in 6-well plates, were 
transduced at an MOI of 2 with the recombinant lentiviruses. 2 days after transduction, 
GFP-expressing cells were sorted by FACS.  
?????? ?????????????????????
Total RNA isolation was performed by using the NucleoSpin RNA kit (Macherey-Nagel, 
Switzerland) according to the manufacturer’s instruction. 200 μg of total RNA from infected 
cells pellet was used for cDNA synthesis using the Omniscript RT Kit (Qiagen, Basel, 
Switzerland).  
Quantitative RT-PCR was performed by using 2 μL of cDNA and 18 μL of Taqman Fast 
universal PCR master mix (Thermo Fisher Scientific, Waltham, MA, USA) containing 
specific primers (20 μM) and probes (5 μM) for human rhinovirus (HRV). 7500 fast Real-
Time PCR System (Thermo Fisher Scientific) was used to perform PCR reactions. The 
ΔΔCT method was used to quantify the mRNA expression levels of endogenous genes.  
The mRNA expression levels of endogenous genes were normalised to the housekeeping 
gene 18S rRNA. Viral RNA copy numbers were obtained through the generation of a 
standard curve obtained with serial dilutions of a plasmid containing HRV cDNA.  
?????? ?????????????????????
Unpaired T-tests were performed using R (version 1.65). 
??? ????????
????? ???????????????????????????????????
We prospectively enrolled 120 previously healthy children admitted to an intensive care 
unit (ICU) for ventilation support due to a common viral respiratory infection. Children with 
known risk factors (prematurity, chronic disease, immunosuppression) were excluded. After 
informed consent was obtained from parents or legal guardians, we collected detailed 
clinical information and laboratory results, as well as biological samples for human DNA 
and RNA analysis (blood) and for viral diagnostics (endotracheal tube aspirate or 
? ???
nasopharyngeal aspirate). The most common clinical presentation was bronchiolitis (88%) 
and the median age was 78 days (range 7 – 828). RSV was the most common pathogen, 
identified in 56% of cases, followed by enteroviruses (rhinovirus / enterovirus) (Table 3.1). 
 
????????????????????????????????????????????????????????
????????????????????????????????????? ????????????????????????????????????????????????????????????????????????
????? ????? ???????? ????? ???????????? ?????????? ??????? ????????? ??????????? ?????? ??????? ??????
?????????????? ?????? ????? ??? ????????? ??????????? ?????? ?????? ???????? ??????????? ????????? ???????
??????????????????????????????????????????????????? ????? ???????????????????????????????????????
 
Age (days)  78 (37 – 269) 
Weight (kg)  5.9 (4.4 – 9.8) 
Country of recruitment Australia 100 (83%) 
Switzerland 20 (17%) 
 
Ethnicity 
Caucasian 90 (78%) 
African 4 (4%) 
Asian 4 (4%) 
Australian  aboriginal 6 (5%) 
Pacific Islander 11 (10%) 
Sex Male 70 (58%) 
Female 50 (42%) 
 
Clinical phenotype 
Bronchiolitis 105 (88%) 
Pneumonia 8 (7%) 
Laryngotracheobronchitis 5 (4%) 
Reactive airway disease 2 (2%) 
 
Virus identified in 
respiratory sample 
RSV 67 (56%) 
Entero/Rhinovirus 31 (26%) 
Adenovirus 17 (14%) 
Human Bocavirus 9 (8%) 
Influenza 2 (2%) 
Parainfluenza 6 (5%) 
Human Metapneumovirus 3 (2%) 
CoV-HKU1 3 (2%) 
CoV-NL63 1 (1%) 
 
Respiratory Support 
High-Flow Nasal Cannulae 99 (83%) 
CPAP or BiPAP 30 (25%) 
Invasive ventilation 31 (26%) 
HFOV 6 (5%) 
Length of PICU stay (days)  2.7 (1.6 – 5.0) 
Expected mortality Pediatric index of mortality 2 (%) 0.02 (0.01 – 0.7) 
Observed mortality Pediatric index of mortality 2 (%) No fatal case 
?
? ???
????? ??????????????????????????????????????????????
For each sample, on average 93% of pass filter reads were unique (not marked as 
duplicate). 96% of pass filter unique reads were aligned to the human reference genome. 
The mean on-bait coverage was 70x with 96% of target bases achieving at least 10x 
coverage and 78% achieving at least 30x coverage (Table 3.2).  
 
???????????????????????????????????? ???????
???????????????????????
  
PF unique 
reads (%) 
 
PF unique 
reads aligned 
(%) 
 
Off-bait 
(%) 
 
Mean bait 
coverage 
(%) 
 
At least 2X 
coverage 
(%) 
 
At least 30X 
coverage (%) 
Average 0.93 0.96 0.22 69.99 0.99 0.78 
SD 0.07 0.04 0.03 15.29 0.01 0.08 
Median 0.96 0.97 0.23 68.04 0.99 0.79 
?
????? ???????????????????????????????
To reduce the number of false positive variants we called variants using three different 
callers: GATK, Platypus and SAMtools. Each callset was annotated and filtered separately 
and only the variants that were called by the three callers and had a missingness rate 
below 5% were kept for downstream analysis. In this final callset we identified 232,591 
SNVs and 103,63 indels including: 951 frame-shift indels, 793 stop-gained and 297 splice-
site variant (Table 3.3).  
?
??????????????????????????? ???????
Variant caller GATK Platypus SAMtools Intersection 
Total variants (%novel) 287681 (16.74%) 271978 (17.72%) 317820 (18.90%) 242954 (14.14%) 
SNV (%novel) 263507 (14.04%) 258548 (16.34%) 296161 (16.63%) 232591 (13.25%) 
indel (%novel) 24174 (46.23%) 13430 (44.34%) 21659 (49.89%) 10363 (34.12%) 
FRAME-SHIFT 1644 1333 1415 951 
STOP-GAINED 880 942 1082 793 
STOP-LOST 89 85 99 76 
START-LOST 126 128 144 112 
SPLICE_SITE 377 353 446 297 
MISSENSE 64057 66559 74945 59144 
INFRAME 1854 1102 1811 867 
SYNONYMOUS 55698 56964 62381 52261 
? ???
UTR 23478 16320 19780 14434 
LoF (%novel) 2635 (49.44%) 2419 (49.89%) 2710 (46.60%) 1878 (41.64%) 
SNP-LoF (%novel) 1116 (30.73%) 1219 (34.12%) 1371 (32.31%) 1023 (30.00%) 
Indel-LoF (%novel) 1519 (63.19%) 1200 (65.91%) 1339 (61.23%) 855 (55.55%) 
 
????? ??????????????????????????
Because they are under strong purifying selection, most LoFs have low frequencies in the 
population. 903 LoFs were found in the intersection of the three callsets. We focused on 
568 of them (456 SNV and 103 indels), which were found at low frequency (MAF<5%) in 
publicly available databases and in an in-house set of 485 exomes. Only 10 of those were 
observed in homozygous form in our study population, impacting 10 different genes (Table 
3.4).  
?
????????????????????????????????????????
????????????????????????????????????????? ?????????????????????????????????????
Chr Position ID Gene Effect 
PRI AF 
(%) 
ExAC 
MAF   
(%) 
ExAC 
het 
1 26301080 rs375730731 PAFAH2 STOP-GAINED 2.083 0.013 
16 
2 163124596 rs35732034 IFIH1 SPLICE-SITE  2.083 0.7 813 
2 186668962 NA FSIP2 FRAME-SHIFT 0.833 0.005 1 
11 18497187 rs145833201 LDHAL6A SPLICE-SITE  0.833 0.094 
112 
17 79974815 rs143008575 ASPSCR1 SPLICE-SITE  0.833 0.087 
102 
20 31659102 rs146981368 BPIFB3 SPLICE-SITE 5.417 0.288 
210 
X 7889837 NA PNPLA4 STOP-GAINED 0.833 0.002 1 
X 127185638 NA ACTRT1 FRAME-SHIFT 2.083 0.199 170 
 
????? ??????????????????????????????
IFIH1 encodes a RIG-I-like cytoplasmic sensor of long double-stranded RNA (dsRNA) and 
plays a chief role in innate immune recognition of RNA viruses (7, 8).  It has been shown 
previously that IFIH1, in combination with RIG-I, recognizes and limits the replication of 
many RNA viruses including: positive single-stranded RNA (ssRNA) viruses especially 
picornaviruses (12, 14–21), negative single-stranded ssRNA viruses including 
paramyxoviruses  (13, 22–25) and double-stranded RNA (dsRNA) viruses  (26).  
? ???
????? ??????????????????????????????????
8 patients in our cohort carried IFIH1 LoF mutations (Table 3.6). A 16-month old previously 
healthy girl was identified to be homozygous for rs35732034. She presented with RSV-
positive respiratory tract infection requiring invasive ventilation. The disease course was 
complicated by superinfection with S. aureus. She showed full recovery and did not require 
further hospitalization outside this event up to age of three years. Her phenotype and 
history was otherwise unremarkable. She showed normal neurodevelopment and has not 
demonstrated any complication with vaccines. A basic immunologic workup including full 
blood count, immunoglobulin levels and IgG subclasses, and lymphocyte subclass counts 
resulted within normal limits. Three infants requiring non-invasive respiratory support for 
bronchiolitis at early infancy were found to be heterozygous for IFIH1 rs35732034. One of 
these manifested recurrent severe viral lower respiratory tract infections leading to 
repeated PICU admissions during early childhood. Three infants (age 1 to 16 months) were 
found to be heterozygous for IFIH1 rs35337543 and required non-invasiave ventilatory 
support for bronchiolitis due to RSV, including one with RSV and HBoV coinfection.  One 
infant requiring invasive ventilation due to enterovirus positive bronchiolitis was 
heterozygous for IFIH1 rs35744605. 
?
??????????????? ????????????????????????
?????????????????????????????????
Chr Position ID Effect   ExAC 
MAF (%) 
PRI AF 
(%) 
  AC 
(hom) 
2 163124596 rs35732034 SPLICE-SITE 0.7 2.08 5 (1) 
2 163134090 rs35744605 STOP-GAIN 0.33 0.42 1 (0) 
2 163136505 rs35337543 SPLICE-SITE 0.65 1.25 3  (0) 
?
????? ????????????????????????? ?????????
Four study participants carried a rare IFIH1 splicing variant, rs35732034: one  homozygous 
and three in heterozygous. We used RNA sequencing to characterize the transcriptomic 
impact of this variant. The minor allele T at rs35732034 causes skipping of exon 14 (IFIH1-
Δ14), which results in a frame shift and an early stop codon in exon 15. The resulting 
protein lacks the final 67 amino acids of wild-type IFIH1, including the C-terminal regulatory 
domain (CTD), which is essential for binding to viral dsRNA. We identified two additional 
rare LoF variants in IFIH1, only present in heterozygous form in a total of four study 
participants: a splicing variant rs35337543 (N=3) and a stop-gained variant rs3574460 
(N=1). RNA sequencing showed that the minor allele G at rs35337543 causes skipping of 
exon 8 (IFIH1-Δ8), which removes 37 amino acids at the end of the conserved helicase 1 
domain and in the linker part between helicase 1 and helicase 2, but does not cause a 
frame shift. rs35744605 is a stop-gained SNV in exon 10 that leads to the loss of 398 
amino acids from the C-terminal end of IFIH1 (IFIH1-ΔCTD) (Figure 3.1 A-C). 
? ???
????? ???????????????????????? ?????????????????????
RNA-seq was performed on 24 biologically independent patient samples, including the 
sample homozygous for rs35732034, two that were heterozygous for this variant and two 
samples heterozygous for rs35337543. The libraries were sequenced to a depth of 98.4 
million paired-end 100 base-pair reads on average (standard deviation (SD): 16.3, range: 
59.5 – 121.4). An average of 84.1 million reads (SD: 13.9, range: 51.1 – 107.9) could be 
uniquely mapped to the reference annotation (Table 3.5). 
?
?????????????????????????? ??????? ???????
               Sample 
 
Uniquely mapped (%) 
Mapped to multiple 
positions (%) 
 
Unmapped (%) 
PRI-019 90.10 5.48 7.32 
PRI‐020 90.71 9.46 4.51 
PRI‐022 107.90 8.24 5.29 
PRI‐024 93.79 9.26 4.64 
PRI‐025 64.80 3.69 2.71 
PRI‐030 90.47 7.99 4.07 
PRI‐031 78.59 8.94 6.06 
PRI‐032 77.96 9.11 5.76 
PRI‐034 102.91 7.98 5.22 
PRI‐038 83.26 5.97 7.43 
PRI‐042 96.83 7.54 6.78 
PRI‐046 73.44 5.78 5.33 
PRI‐047 81.99 27.25 8.44 
PRI‐049 95.66 6.59 9.49 
PRI‐050 79.92 7.00 6.92 
PRI‐051 84.27 8.51 7.76 
PRI‐060 70.86 7.15 4.49 
PRI‐061 51.11 4.91 3.48 
 
 
 
 
 
 
?
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? ???
????? ?????????????????????????????????????????? ?????????
To functionally characterize the identified variants, we first measured the ability of wild type 
(IFIH1-wt) and mutant IFIH1 isoforms to induce interferon β (IFNβ) in vitro. We transfected 
plasmids carrying IFIH1-wt, IFIH1-Δ8, IFIH1-Δ14 and IFIH1-ΔCTD into 293T cells, 
Overexpression of IFIH1-wt, but not of any of the mutant IFIH1 isoforms, led to IFNβ 
induction. Co-transfection of IFIH1-wt with each of the mutant IFIH1 isoforms showed a 
slight interference with IFIH1-wt induced IFNβ production (Figure 2A). We then checked 
the stability of the various IFIH1 protein isoforms by performing pulse-chase experiments in 
transfected 293T cells. The three mutant isoforms were less stable than IFIH1-wt (Figure 
2B) and had a negative impact on the stability of the wild type isoform when co-transfected 
(Figure 2C). Finally, we tested the ATPase activity of recombinant IFIH1-wt and mutant 
IFIH1 isoforms. IFIH1-wt was able to hydrolyze ATP and showed a typical dsRNA-
dependent increase in enzymatic activity, while the mutant isoforms had no detectable 
activity, even upon stimulation with polyinosinic:polycytidylic acid (polyI:C), a synthetic 
analogue of double-stranded RNA (Figure 2D). Furthermore, all mutant isoforms decreased 
IFIH1-wt ATPase activity in a dose-dependent manner, an interference that was specific to 
mutant IFIH1 isoforms, as demonstrated by the absence of any effect of bovine serum 
albumin on IFIH1-wt ATPase activity (Figure 2E-F). Jointly, these experiments demonstrate 
that the three putative LoF variants identified in our study population lead to severe 
disruption of IFIH1 signalling function, protein stability and enzymatic activity in vitro. In 
addition, the observations that the mutant IFIH1 isoforms interfere with the wild type protein 
in terms of IFNβ induction, protein stability and enzymatic activity suggest a potential 
dominant negative role for heterozygous LoF variants in IFIH1.  
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Viral testing of respiratory samples showed that six of the patients harboring IFIH1 LoF 
alleles were infected with RSV and two with human rhinovirus (HRV). To study the effect of 
IFIH1 on RSV and HRV replication, we used Huh7.5 cells, which lack endogenous 
expression of IFIH1 and express a mutated, inactive form of RIG-I, and thus are completely 
unreactive to the RNA pathogen-associated molecular patterns that normally activate these 
pathways (11). The cells were transduced with an IFIH1-expressing lentiviral vector. We 
observed a much higher level of viral replication in native than in IFIH1-transduced Huh7.5 
cells upon infection with HRV-B14, HRV-A16 (Figure 3A-B). The role of IFIH1 in HRV 
restriction was further demonstrated by 35S labelling of infected cells, which showed a 
stronger shutoff of cellular protein synthesis in native than in IFIH1-transduced Huh7.5 
cells, due to higher replication of HRV-B14 in the absence of IFIH1 (Figure 3C). We 
observed a much higher level of viral replication in native than in IFIH1-transduced Huh7.5 
cells upon RSV infection (Figure 3D-F). We also measured RSV replication in mouse 
embryonic fibroblasts (MEFs), ifih1(+/+), and in IFIH1-knock out MEFs, ifih1(-/-), and 
obtained similar results (Figure 3G-I). Together, these results affirm the central role of 
IFIH1 in innate immune recognition of RSV and HRV (12, 13). Therefore, LoF variants in 
IFIH1 can be reasonably expected to increase susceptibility to these viruses. 
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It has been shown previously that rare human genetic variants can cause pathogen 
specific primary immunodeficiencies or confer predisposition to a narrow range of 
infections in otherwise healthy individuals (19–26). We hypothesized that extreme 
susceptibility to common viral respiratory infection – a rare, potentially lethal phenotype – 
could also reflect an underlying immunodeficiency. Using an unbiased exome-wide 
approach in carefully selected study participants, we identified a rare monogenic defect 
predisposing to severe clinical presentations of RSV and enterovirus/rhinovirus infections. 
Three deleterious variants were observed in IFIH1, which encodes a cytoplasmic receptor 
critical for viral RNA sensing. The IFIH1 protein binds to dsRNA in an ATP-dependent 
manner, and initiates a signalling cascade that leads to type 1 interferon production, a 
process that is disrupted in the presence of any of the LoF variants found in our study 
population. Interestingly, all three have been shown to be protective against type 1 
diabetes (27). Common IFIH1 variants have also been associated with diabetes and other 
autoimmune diseases (28–30), as well as with hepatitis C virus (HCV) clearance (31). 
Additionally, rare gain-of-function mutations in IFIH1 dramatically upregulate type I 
interferon production, resulting in Aicardi-Goutières syndrome or Singleton-Merten 
syndrome (32–34). Considered together, the results from all these human genetic studies 
underscore the pivotal role of innate immune activation in the intricate balance between 
host defense, inflammation and autoimmunity. 
LoF variants in IFIH1 were only found in a minority of the 120 children enrolled in our study, 
suggesting that other genetic or non-genetic risk factors remain to be discovered. Genetic 
heterogeneity is likely to be the rule rather than the exception in extreme presentations of 
infectious diseases, and larger sample sizes will be required to identify exceedingly rare 
causal alleles. Whole genome sequencing will also be needed to obtain a more complete 
coverage of exonic regions (35), and to explore non-coding and large-scale structural 
variation.  
The elucidation of the human genetic basis of severe infection provides mechanistic insight 
into pathogenesis and innate immune response. An immediate practical implication is the 
possibility to develop diagnostic assays to identify susceptible individuals that could benefit 
from specific preventive and interventional measures. By highlighting the genes and 
pathways that play an essential role in host-pathogen interaction, genetic discovery in 
individuals with extreme phenotypes also provides the opportunity to design new 
therapeutic strategies that could be useful for the vast majority of patients with milder 
clinical presentation. 
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Human Respiratory Syncytial Virus (RSV) is the leading cause of lower respiratory tract 
infection in children worldwide. Between 50 and 70% of newborns get infected with RSV 
within their first year of life and almost all children suffer from RSV infection before the age 
of two (1, 2). RSV belongs to the family paramyxoviridae. It is an enveloped, negative-
sense RNA virus with a single-stranded genome of approximately 15 kb (3). The 
nonsegmented RSV genome encodes 11 proteins. Small hydrophobic protein (SHpr), 
fusion glycolprotein (Fpr) and attachment glycoprotein (Gpr) are transmembrane 
glycoproteins. Fpr and Gpr are the two major glycoproteins on RSV’s surface that mediates 
the attachment and entry of the virus to the host cells. Matrix protein (Mpr) is an internal 
membrane associated matrix protein; nucleoprotein (Npr), phosphoprotein (Ppr), matrix 
M2-1 protein (M2-1pr) and RNA polymerase (Lpr) are components of the 
nucleocapsid/polymerase complex; nonstructural protein 1 and 2 (NS1 and NS2) are 
presumptive nonstructural proteins that act against the host immune system; and matrix 
M2-2 protein (M2-2pr) is a low abundance protein that is suspected to play a regulatory 
role in RNA transcription and translation (4, 5). There are two main RSV strains: RSVA and 
RSVB. At the serological level, the two strains are characterized by different antibody 
responses against Fpr and Gpr (6). Each strain is further subdivided into different 
genotypes according to phylogenetic analyses of specific genomic regions. 
In the vast majority of cases, RSV infection manifests itself as a normal cold, with 
spontaneous resolution of respiratory symptoms after a few days (7).  Beside socio-
economic and environmental factors (e.g. mal-nutrition and smoking parents), a number of 
risk factors have been described for severe susceptibility to respiratory viruses including 
male gender, preterm birth, chronic diseases and immune suppression (8–11). However, 
approximately 1 out of 1000 children without any known risk factor or co-morbidity requires 
intensive care support due to life-threatening manifestations of RSV infection. Our recent 
work showed that rare protein truncating mutations in the IFIH1 gene lead to extreme 
susceptibility to RSV in a subset of otherwise healthy children (Asgari et al., submitted). A 
? ???
number of earlier studies focused on RSV genetic diversity and suggested that the severity 
of RSV infection depends in part on viral strain or in a few cases on variations of large 
effects (deletions and duplications) in the viral genome (12–14).  
Here, we sequence and reconstruct the complete genomes of two RSV strains found in 
children with very severe RSV disease, who have also been fully characterized at the 
exome and blood transcriptome levels. We further compare them with 53 recently 
sequenced RSV genomes isolated mainly from patients with mild symptoms (15). This 
study aims at establishing a framework to explore the genetic diversity of RSV strains 
recovered from patients with unusually severe disease, in an attempt to determine whether 
viral genetic factors are partly responsible for the most severe clinical presentations. 
??? ????????????? ???????
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Study participants were recruited at the Royal Children’s Hospital (RCH) and Mater 
Children’s Hospital (MCH) in Brisbane, Australia, in 2013. The study was approved by the 
relevant Ethics Commissions and written informed consent was obtained from parents or 
legal guardian. A nasopharyngeal aspirate (NPA) was collected from previously healthy 
children who needed admission to the intensive care unit (ICU) and ventilation support due 
to severe lower respiratory tract RSV infection. Viral RNA was extracted individually (100ul 
sample + 300ul PBS) using the NucliSens Easymag© according to the manufacturer's 
instructions. Respiratory virus screening was performed using the FTD Respiratory 
pathogens 21 assay on a Viia7 instrument. The viral strain was determined prior to 
sequencing using PCR with strain specific primers.  
????? ?????????????????????
We sequenced one sample positive for RSVA (PRI-024) and one sample positive for RSVB 
(PRI-030). The number of viral RNA copies was inferior to the limit of detection of the 
quantitative PCR assay. Ribosomal RNA (rRNA) was removed using a Ribo-Zero Gold kit 
according to the manufacturer's protocol. rRNA-depleted specimens were purified on Zymo 
columns. Libraries were prepared with the low-throughput TruSeq total RNA preparation 
protocol from Illumina using 15 PCR cycles. Library concentrations were measured with Q-
bit. Size distribution of fragments was estimated with  2200 TapeStation. Fragments of 200 
to 450 bp were obtained. All specimens were sequenced paired-end using the 100-bp 
protocol with indexing on a HiSeq 2500 sequencer in pools of two specimens per lane. 
RNA-seq libraries were loaded at 8 pM.  
????? ??????????????????????????????
Short reads from each sample were mapped to the human reference genome GRCh37 to 
identify and remove human sequences. Unmapped paired-end reads were extracted and 
used for de novo assembly using the default options of CLC genomics workbench 
(https://www.qiagenbioinformatics.com/). To make contigs, the CLC genomics workbench de 
novo assembler used Bruijn graphs, an efficient algorithm allowing fast contig formation. 
The basic idea is to hash the reads according to a predefined k-mer length called word 
? ???
size. In the next step, for a word size of k the algorithm will find all the neighbouring words 
of k-1 overlapping ends. The ideal word size is a balance between specificity and 
sensitivity.  A de Bruijn graph is made of each word as a node and each neighbour as an 
edge. In an ideal situation only one forward neighbour and one backward neighbour is 
available for each word and long, linear stretches of connected nodes can be made. In 
many situations, however, many nodes have more than one incoming or outgoing edge. 
The de Bruijn graph is resolved by following a Eulerian trail in the graph, a trail that visits 
every edge exactly once.  For de novo assembly we used the word size of 23 and 
minimum contig length of 2500 bp.  To identify the produced contigs we used the 
generated contigs as query sequences for NCBI nucleotide BLAST to find the best 
matches to the query sequences, defined as matches with the lowest E-value and the 
highest sequence similarity. 
????? ??????????????????????????????????????
The newly sequenced and assembled genomes were compared with 53 complete RSV 
genomes (34 RSVA and 19 RSVB, BioProject PRJNA73049, Table 4.3). These 53 
sequences are fully characterized RSV genomes from respiratory samples collected in 
Mexico, Argentina, Belgium, Italy, Germany, Australia, South Africa, and the USA between 
1998-2010. These samples were collected from adult and infant patients with normal / mild 
clinical presentation of the disease to investigate RSV genomic diversity. Multiple 
alignments of PRI-024 and PRI-030 genome sequence with these publically available 
genomes were used for inferring a maximum likelihood tree with 100 bootstraps using CLC 
genomics workbench.  
????? ????????????????????????????
PRI-024 and PRI-030 were annotated for ORF using VIGOR (http://jcvi.org/vigor/index.php) 
and the sequence of each of the 11 RSV proteins was obtained.  We annotated the 34 
RSVA and 19 RSVB listed in table 4.3 and obtained a consensus sequence for each RSV 
protein by multiple alignments of these protein sequences. We used dot plots to search for 
gaps or stretches of low similarity between our samples and the consensus protein 
sequences from the above-mentioned RSV genomes. To look for single amino acid 
changes, we used multiple alignments of our samples and the 34 RSVA and 19 RSVB 
listed in table 4.3. 
??? ????????
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Sample PRI-024 was extracted from a 72 day old female and sample PRI-030 was 
extracted from a 21 day old male, both of recent Western European ancestry. They 
required ICU admission and non-invasive ventilatory support for respiratory symptoms 
attributed to RSV bronchiolitis. No co-infection or co-morbidity was reported. Both had a full 
recovery and their medical history was otherwise unremarkable. A separate analysis of 
their germline DNA (by exome sequencing) and transcriptome (by RNA sequencing) did 
? ???
not reveal any information that could explain the severity of the presentation (Asgari et al., 
submitted). 
????? ?????????????????????
For PRI-024, 149,805,670 paired-end reads were obtained. 96.2% of reads had phred 
scale sequence quality score ≥ 20 (88.5% ≥ 30). 64% of the reads were mapped to the 
human reference genome. 30% of the reads were paired-end reads that were not mapped 
to human genome. 
For PRI-030, 144,588,304 paired-end reads were obtained. 96.5% of reads had phred 
scale sequence quality score ≥ 20 (86% ≥ 30). 47.2% of the reads were mapped to human 
reference genome. 49.6% of the reads were paired-end reads that were not mapped to 
human genome. 
????? ??????????????????????????????
For de novo assembly we used all paired-end reads that were not mapped to human 
reference genome (the reads that were mapped to human reference genome and all the 
single reads were removed). For PRI-024, 45,018,680 paired-end reads were used. N50 
was 3,247 and the longest contig was 15,219 bp, resulting from the assembly of 5,388,825 
reads (11.97% of reads) (Figure 4.1 A and C). For PRI-030 71,837,152 paired-end reads 
were used. N50 was 3,281 and the longest contig was 15,321 bp, resulting from the 
assembly of 4,988,115 reads (6.94% of reads) (Figure 4.1 B and D). In both cases, the 
longest contig had a high coverage (34000x on average) and matched the expected length 
of the RSV genome.  
To identify the reconstructed contigs we used them as query sequences for nucleotide 
BLAST against the NCBI nucleotide database. For PRI-024, 72 contigs with length > 
2500bp was generated. For the longest PRI-024 contig, a human RSVA was the best 
match (accession: KJ627365). For PRI-030, 44 contigs with length > 2500bp was 
generated. For PRI-030 the longest PRI-030 longest contig a human RSVB was the best 
match (accession: JX576745). The BLAST analysis of these contigs allowed the 
identification of additional viral and bacterial species in the samples. Most had no known 
correlation with respiratory infections, but a single contig in PRI-030 showed high similarity 
to Moraxella catarrhalis strain 25240. (Table 4.1 and 4.2) 
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Query 
Lowest 
E-value 
Accession for 
lowest E-value 
Description for lowest E-value 
PRI-024_contig_1 0 KJ627365 Human respiratory syncytial virus strain RSVA 
PRI-024_contig_2 0 HF558455 Rhodotorula taiwanensis RS1 
PRI-024_contig_3 0 LK052953 Rhodosporidium toruloides strain CECT1137 
PRI-024_contig_4 0 HF558455 Rhodotorula taiwanensis RS1 
PRI-024_contig_5 0 HF558455 Rhodotorula taiwanensis RS1 
PRI-024_contig_6 0 XM_002548769 
Candida tropicalis MYA-3404 C-1-tetrahydrofolate 
synthase 
PRI-024_contig_7 0 XM_002616278 
Clavispora lusitaniae ATCC 42720 conserved 
hypothetical protein 
PRI-024_contig_8 0 XM_001382415 
Scheffersomyces stipitis CBS 6054 plasma membrane 
H+ATPase 
PRI-024_contig_9 0 XM_007385036 
Punctularia strigosozonata HHB-11173 SS5 
hypothetical protein, (PUNSTDRAFT_104183) 
PRI-024_contig_10 0 LK052965 Rhodosporidium toruloides strain CECT1137 
PRI-024_contig_11 0 KR055655 
Pseudogymnoascus pannorum strain NN050741 
mitochondrion 
PRI-024_contig_12 6.5E-169 LK052940 
Rhodosporidium toruloides strain CECT1137, 
genomic scaffold 
PRI-024_contig_13 0 HF558455 
Rhodotorula taiwanensis RS1, complete mitochondrial 
genome 
PRI-024_contig_14 0 XM_007917050 
Togninia minima UCRPA7 putative plasma membrane 
atpase protein mRNA 
? ???
PRI-024_contig_15 0 LK052936 
Rhodosporidium toruloides strain CECT1137, 
genomic scaffold, scaffold, RHTO0S01 
PRI-024_contig_16 3.7E-69 XM_001483899 
Meyerozyma guilliermondii ATCC 6260 hypothetical 
protein (PGUG_03330) partial RNA 
PRI-024_contig_17 9.6E-83 CP003834 
Cryptococcus neoformans var. grubii H99 
mitochondrion, complete genome 
PRI-024_contig_18 0 XM_002548335 
Candida tropicalis MYA-3404 elongation factor 3, 
mRNA 
PRI-024_contig_19 5.3E-143 LK052943 
Rhodosporidium toruloides strain CECT1137, 
genomic scaffold, scaffold, RHTO0S08 
PRI-024_contig_20 0 FQ311441 
Sporisorium reilianum SRZ2 chromosome 2 complete 
DNA sequence 
PRI-024_contig_21 6E-161 XM_009547565 
Heterobasidion irregulare TC 32-1 oligopeptide 
transporter mRNA 
PRI-024_contig_22 0 XM_014321648 
Trichosporon asahii var. asahii CBS 2479 delta-9 fatty 
acid desaturase partial RNA 
PRI-024_contig_23 0 LK052949 
Rhodosporidium toruloides strain CECT1137, 
genomic scaffold, scaffold, RHTO0S14 
PRI-024_contig_24 0 LK052954 
Rhodosporidium toruloides strain CECT1137, 
genomic scaffold, scaffold, RHTO0S19 
PRI-024_contig_25 0 CP000502 
Scheffersomyces stipitis CBS 6054 chromosome 8, 
complete sequence 
PRI-024_contig_26 0 HF558455 
Rhodotorula taiwanensis RS1, complete mitochondrial 
genome 
PRI-024_contig_27 0 LK052942 
Rhodosporidium toruloides strain CECT1137, 
genomic scaffold, scaffold, RHTO0S07 
PRI-024_contig_28 0 LK052939 
Rhodosporidium toruloides strain CECT1137, 
genomic scaffold, scaffold, RHTO0S04 
PRI-024_contig_29 0 XM_013568353 
Aureobasidium namibiae CBS 147.97 hypothetical 
protein partial mRNA 
PRI-024_contig_30 0 LK052951 
Rhodosporidium toruloides strain CECT1137, 
genomic scaffold, scaffold, RHTO0S16 
PRI-024_contig_31 0 LK052965 
Rhodosporidium toruloides strain CECT1137, 
genomic scaffold, scaffold, RHTO0S30 
? ???
PRI-024_contig_32 0 LK052940 
Rhodosporidium toruloides strain CECT1137, 
genomic scaffold, scaffold, RHTO0S05 
PRI-024_contig_33 0 LK052945 
Rhodosporidium toruloides strain CECT1137, 
genomic scaffold, scaffold, RHTO0S10 
PRI-024_contig_34 0 LK052940 
Rhodosporidium toruloides strain CECT1137, 
genomic scaffold, scaffold, RHTO0S05 
PRI-024_contig_35 0 KC616429 
Scheffersomyces coipomoensis isolate NRRL_Y-
17651 endogenous virus ScV, putative proteins and 
tryptophan-2,3-dioxygenase genes, complete cds 
PRI-024_contig_36 0 LK052940 
Rhodosporidium toruloides strain CECT1137, 
genomic scaffold, scaffold, RHTO0S05 
PRI-024_contig_37 0 CP012999 Enterobacter sp. E20, complete genome 
PRI-024_contig_38 0 XM_007374069 
Spathaspora passalidarum NRRL Y-27907 
hypothetical protein, (SPAPADRAFT_134536), partial 
mRNA 
PRI-024_contig_39 0 XM_002545697 
Candida tropicalis MYA-3404 
phosphoribosylformylglycinamidine synthase, mRNA 
PRI-024_contig_40 0 XM_007372211 
Spathaspora passalidarum NRRL Y-27907 beta-1,3-
glucan synthase, (SPAPADRAFT_145419), mRNA 
PRI-024_contig_41 0 LK052948 
Rhodosporidium toruloides strain CECT1137, 
genomic scaffold, scaffold, RHTO0S13 
PRI-024_contig_42 0 XM_014800750 
Pseudozyma antarctica carbamoyl-phosphate 
synthase partial mRNA 
PRI-024_contig_43 0 XM_006965283 
Trichoderma reesei QM6a predicted protein 
(TRIREDRAFT_121820), mRNA 
PRI-024_contig_44 5.8E-67 LK052938 
Rhodosporidium toruloides strain CECT1137, 
genomic scaffold, scaffold, RHTO0S03 
PRI-024_contig_45 0 XM_014803277 
Pseudozyma antarctica family 3 glycosyltransferase 
partial mRNA 
PRI-024_contig_46 1.4E-131 LK052942 
Rhodosporidium toruloides strain CECT1137, 
genomic scaffold, scaffold, RHTO0S07 
PRI-024_contig_47 0 XM_007374531 
Spathaspora passalidarum NRRL Y-27907 
hypothetical protein, (SPAPADRAFT_66085),  mRNA 
? ???
PRI-024_contig_48 0 XM_014797905 
Pseudozyma antarctica Na/K ATPase alpha 1 subunit 
partial mRNA 
PRI-024_contig_49 0 FQ311435 
Sporisorium reilianum SRZ2 chromosome 14 
complete DNA sequence 
PRI-024_contig_50 0 XM_013566968 
Aureobasidium namibiae CBS 147.97 hypothetical 
protein partial mRNA 
PRI-024_contig_51 0 XM_007373532 
Spathaspora passalidarum NRRL Y-27907 
hypothetical protein, (SPAPADRAFT_49095), partial 
mRNA 
PRI-024_contig_52 0 LK052939 
Rhodosporidium toruloides strain CECT1137, 
genomic scaffold, scaffold, RHTO0S04 
PRI-024_contig_53 0 LK052936 
Rhodosporidium toruloides strain CECT1137, 
genomic scaffold, scaffold, RHTO0S01 
PRI-024_contig_54 0 LK052949 
Rhodosporidium toruloides strain CECT1137, 
genomic scaffold, scaffold, RHTO0S14 
PRI-024_contig_55 0 AB920149 
Cryptococcus tepidarius gene for plasma membrane 
H(+)-ATPase 1, complete, sequence, strain: JCM 
11965 
PRI-024_contig_56 0 LK052939 
Rhodosporidium toruloides strain CECT1137, 
genomic scaffold, scaffold, RHTO0S04 
PRI-024_contig_57 4.9E-68 LK052943 
Rhodosporidium toruloides strain CECT1137, 
genomic scaffold, scaffold, RHTO0S08 
PRI-024_contig_58 0 LK052941 
Rhodosporidium toruloides strain CECT1137, 
genomic scaffold, scaffold, RHTO0S06 
PRI-024_contig_59 0 LK052886 
Cyberlindnera fabianii strain YJS4271 genomic 
scaffold, scaffold CYFA0S01 
PRI-024_contig_60 4.6E-05 CP012620 
Oryza sativa Indica Group cultivar RP Bio-226 
chromosome 12 sequence 
PRI-024_contig_61 0 XM_007880608 
Pseudozyma flocculosa PF-1 hypothetical protein 
partial mRNA 
PRI-024_contig_62 0.32 XM_013458970 
Exophiala xenobiotica dihydroxy-acid dehydratase 
mRNA 
PRI-024_contig_63 0 XM_001383177 
Scheffersomyces stipitis CBS 6054 glycine cleavage 
system protein partial mRNA 
PRI-024_contig_64 0 LK052940 
Rhodosporidium toruloides strain CECT1137, 
genomic scaffold, scaffold, RHTO0S05 
? ???
PRI-024_contig_65 0 LK052945 
Rhodosporidium toruloides strain CECT1137, 
genomic scaffold, scaffold, RHTO0S10 
PRI-024_contig_66 0 LK052946 
Rhodosporidium toruloides strain CECT1137, 
genomic scaffold, scaffold, RHTO0S11 
PRI-024_contig_67 0 XM_014318297 
Grosmannia clavigera kw1407 elongation factor 3 
partial mRNA 
PRI-024_contig_68 0 LK052938 
Rhodosporidium toruloides strain CECT1137, 
genomic scaffold, scaffold, RHTO0S03 
PRI-024_contig_69 9.7E-78 XM_007372681 
Spathaspora passalidarum NRRL Y-27907 ran 
binding protein, (SPAPADRAFT_53613), partial 
mRNA 
PRI-024_contig_70 0 LK052939 
Rhodosporidium toruloides strain CECT1137, 
genomic scaffold, scaffold, RHTO0S04 
PRI-024_contig_71 0 LK052953 
Rhodosporidium toruloides strain CECT1137, 
genomic scaffold, scaffold, RHTO0S18 
PRI-024_contig_72 8.8E-65 LK052944 
Rhodosporidium toruloides strain CECT1137, 
genomic scaffold, scaffold, RHTO0S09 
?
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Query 
Lowest 
E-value 
Accession for 
lowest E-value 
Description for lowest E-value 
PRI-030_contig_1 0 JX576745 
Human respiratory syncytial virus strain 08-045952 
from Netherlands, complete genome 
PRI-030_contig_2 0 CP007457 
Bifidobacterium pseudolongum PV8-2, complete 
genome 
PRI-030_contig_3 0 DQ831892 
Fusarium oxysporum f. sp. lactucae isolate FK09701 
28S ribosomal RNA gene, partial sequence; 28S- 18S 
ribosomal RNA intergenic spacer, complete 
sequence; and 18S ribosomal RNA gene, partial 
PRI-030_contig_4 0 XM_001382817 
Scheffersomyces stipitis CBS 6054 Elongation factor 
partial mRNA 
PRI-030_contig_5 0 AM905426 Bacterium Ellin514 23S rRNA gene, isolate Ellin514 
PRI-030_contig_6 0 CP000094 Pseudomonas fluorescens Pf0-1, complete genome 
? ???
PRI-030_contig_7 1.8E-09 AM087550 
Ophiostoma mitovirus 3b RdRp gene for RNA- 
dependent RNA polymerase, genomic RNA 
PRI-030_contig_8 0 CP012752 
Kibdelosporangium phytohabitans strain 
KLBMP1111, complete genome 
PRI-030_contig_9 0 HF558455 
Rhodotorula taiwanensis RS1, complete 
mitochondrial genome 
PRI-030_contig_10 0 AY874423 
Fusarium oxysporum voucher VPRI 19292 
mitochondrion, partial genome 
PRI-030_contig_11 0 XM_012193664 
Cryptococcus neoformans var. grubii H99 elongation 
factor 3 mRNA 
PRI-030_contig_12 0 CP001630 
Actinosynnema mirum DSM 43827, complete 
genome 
PRI-030_contig_13 0 X73672 
T.papilionaceus mitochondrion gene for large subunit 
rRNA, exons 1 and 2 
PRI-030_contig_14 0 HF679031 
Fusarium fujikuroi IMI 58289 draft genome, 
chromosome FFUJ_chr09 
PRI-030_contig_15 0 XM_013570087 
Aureobasidium namibiae CBS 147.97 elongation 
factor 3 partial mRNA 
PRI-030_contig_16 0 XM_013575636 
Aureobasidium namibiae CBS 147.97 hypothetical 
protein partial mRNA 
PRI-030_contig_17 0 HF679024 
Fusarium fujikuroi IMI 58289 draft genome, 
chromosome FFUJ_chr02 
PRI-030_contig_18 0.007 CP001843 Treponema primitia ZAS-2, complete genome 
PRI-030_contig_19 0 KJ807813 
Bean common mosaic virus isolate PStV-JX014, 
complete genome 
PRI-030_contig_20 0 CP007155 Kutzneria albida DSM 43870, complete genome 
PRI-030_contig_21 0 HE804045 
Saccharothrix espanaensis DSM 44229 complete 
genome 
PRI-030_contig_22 0 XM_013568353 
Aureobasidium namibiae CBS 147.97 hypothetical 
protein partial mRNA 
PRI-030_contig_23 0 HF558455 
Rhodotorula taiwanensis RS1, complete 
mitochondrial genome 
PRI-030_contig_24 0 HF558455 
Rhodotorula taiwanensis RS1, complete 
mitochondrial genome 
PRI-030_contig_25 4.7E-169 LK052940 
Rhodosporidium toruloides strain CECT1137, 
genomic scaffold, scaffold RHTO0S05 
PRI-030_contig_26 1E-164 XM_013586131 
Medicago truncatula mu-like prophage flumu protein 
gp28 partial mRNA 
PRI-030_contig_27 0 KT598234 
Soybean-associated single stranded RNA virus 2 
isolate SaSSRV2-1, partial sequence 
PRI-030_contig_28 6.9E-136 CP003834 
Cryptococcus neoformans var. grubii H99 
mitochondrion, complete genome 
? ???
PRI-030_contig_29 0 LK052953 
Rhodosporidium toruloides strain CECT1137, 
genomic scaffold, scaffold RHTO0S18 
PRI-030_contig_30 0 CP000094 Pseudomonas fluorescens Pf0-1, complete genome 
PRI-030_contig_31 0 HF679026 
Fusarium fujikuroi IMI 58289 draft genome, 
chromosome FFUJ_chr04 
PRI-030_contig_32 0 LK052944 
Rhodosporidium toruloides strain CECT1137, 
genomic scaffold, scaffold RHTO0S09 
PRI-030_contig_33 0.2 XM_010538616 
PREDICTED: Tarenaya hassleriana zinc finger 
protein 2 (LOC104811796), mRNA 
PRI-030_contig_34 0 CP003880 Pseudomonas sp. UW4, complete genome 
PRI-030_contig_35 0 HF679025 
Fusarium fujikuroi IMI 58289 draft genome, 
chromosome FFUJ_chr03 
PRI-030_contig_36 1.3E-36 CP007410 
Pseudomonas brassicacearum strain DF41, 
complete genome 
PRI-030_contig_37 0 CP009290 
Pseudomonas chlororaphis subsp. aurantiaca strain 
JD37, complete genome 
PRI-030_contig_38 0 XM_007006344 
Tremella mesenterica DSM 1558 plasma membrane 
H+ ATPase (TREMEDRAFT_40283), mRNA 
PRI-030_contig_39 0 LK052942 
Rhodosporidium toruloides strain CECT1137, 
genomic scaffold, scaffold RHTO0S07 
PRI-030_contig_40 8E-104 CP003170 Actinoplanes sp. SE50/110, complete genome 
PRI-030_contig_41 0 CP012999 Enterobacter sp. E20, complete genome 
PRI-030_contig_42 0 CP000094 Pseudomonas fluorescens Pf0-1, complete genome 
PRI-030_contig_43 0 HE804045 
Saccharothrix espanaensis DSM 44229 complete 
genome 
PRI-030_contig_44 0 CP008804 
Moraxella catarrhalis strain 25240, complete 
genome 
 
????? ???????????????????????????????????
After multiple sequence alignment of PRI-024 with RSVA sequences and of PRI-030 with 
RSVB sequences listed in table 4.3 we used a maximum likelihood approach to infer the 
phylogenic tree for both RSV genomes. Each tree includes viruses that have already been 
assigned to genotypes GA5 and GA2 for RSVA and BA for RSVB. PRI-024 clustered with 
GA2, which is one of the predominant circulating RSVA genotypes. PRI-030 clustered with 
BA genotype, the dominant genotype for RSVB worldwide (15) (Figure 4.2). 
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Sample 
 
Strain 
 
Year collected 
 
Genome size 
 
Identity with de 
novo assembled 
RSV (%) 
KF530258 RSVA 2007 15123 98.28 
KF530260 RSVA 2005 14980 94.19 
KF530261 RSVA 2008 15100 98.23 
KF530263 RSVA 2007 15118 98.08 
KF530264 RSVA 2008 15039 98.02 
KF530267 RSVA 2007 15078 96.30 
KF530268 RSVA 2007 15128 94.81 
KF530269 RSVA 2009 15049 97.89 
KF826816 RSVA 2005 14948 92.87 
KF826817 RSVA 2009 14744 93.43 
KF826821 RSVA 2007 15177 98.39 
KF826823 RSVA 1998 15197 95.34 
KF826824 RSVA 1998 15200 95.23 
KF826826 RSVA 2004 15197 95.08 
KF826827 RSVA 2004 15209 95.10 
KF826828 RSVA 2004 15191 95.13 
KF826830 RSVA 2009 15186 98.39 
KF826831 RSVA 2009 15195 98.35 
KF826832 RSVA 2009 15176 95.04 
KF826833 RSVA 2009 15129 98.50 
KF826836 RSVA 2006 15165 94.87 
KF826837 RSVA 2006 15194 95.02 
KF826838 RSVA 2006 15189 98.45 
KF826840 RSVA 2007 15106 97.84 
KF826841 RSVA 2007 15194 95.05 
KF826846 RSVA 2008 15142 94.90 
KF826847 RSVA 2007 15179 95.36 
KF826848 RSVA 2007 15190 97.36 
KF826849 RSVA 2010 15182 98.52 
KF826850 RSVA 2008 15193 95.01 
KF826852 RSVA 2007 15167 95.04 
KF826854 RSVA 2009 15192 94.89 
KF826855 RSVA 2009 15163 98.74 
KF826856 RSVA 2009 15188 98.59 
KF530259 RSVB 2006 15157 98.45 
???
KF530262 RSVB 2009 15045 97.60 
KF530266 RSVB 2008 15064 97.78 
KF826820 RSVB 2009 15181 94.66 
KF826822 RSVB 2007 15269 98.80 
KF826825 RSVB 2004 15259 98.13 
KF826829 RSVB 2005 15215 97.72 
KF826834 RSVB 2009 15218 98.31 
KF826835 RSVB 2009 15238 96.43 
KF826839 RSVB 2006 15278 98.63 
KF826842 RSVB 2007 15269 98.72 
KF826843 RSVB 2008 15280 98.47 
KF826844 RSVB 2008 15218 98.24 
KF826845 RSVB 2008 15147 97.78 
KF826851 RSVB 2007 15279 98.79 
KF826853 RSVB 2008 15183 96.43 
KF826857 RSVB 2009 15278 98.71 
KF826858 RSVB 2009 15233 98.73 
KF826860 RSVB 2009 15249 98.54 
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We annotated the ORFs of our two reconstructed RSV genomes and obtained the 
sequence of the 11 RSV proteins. We compared these protein sequences with consensus 
sequences derived from RSVA proteins in GA2 clade for PRI-024 (15 genomes) and BA 
clade for PRI-030 (18 genomes). For both strains all proteins were highly similar to 
consensus sequence proteins in amino acid composition, amino acid sequence and protein 
sequence length (Figure 4.3 and 4.4).  To get a more detailed picture of RSV protein 
variation we also performed a multiple alignment of PRI-024 and PRI-030 proteins with 
other genomes in the same clade and for each protein listed the number of unique amino 
acids changes. Unique changes were defined as amino acid changes that were observed 
only once in multiple alignment. Neither PRI-024 nor PRI-030 showed unusually higher 
variability (Table 4.4).  
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Sample NS1 NS2 N P M SH G F   M2-1  M2-2 L 
Total 
unique 
changes 
PRI-024 - - - - - - 6 - - - 3 9 
KF826833 - - - - - - 1 - - - 1 2 
KF826855 - - - - - - - 1 - - - 1 
KF826849 - - - - - - - - - - - 0 
KF530269 - - - - - - - - - - - 0 
KF826817 - - - - 1 - 1 2 - 1 - 5 
KF826856 - - - - - - 1 - 1 - - 2 
KF530264 - 1 - - - - - - - 1 - 2 
KF530261 - - - - - - 3 - - 1 1 5 
KF826830 - 1 1 - 1 - 2 4 1 1 1 12 
KF826831 - 1 - - - - 3 - 1 - 2 7 
KF826838 - - - - - - 1 - - - 1 2 
KF530258 - - - - - - - - - - 2 2 
KF826840 - - - - - - 1 1 - - 2 4 
KF530263 - - - - - - - 6 - - 8 14 
KF826848 1 1 - - - - 12 5 - 5 3 27 
PRI-030 - - - - - - 2 1 - - 4 7 
KF826842 - - 1 1 - - 5 1 - - 3 11 
KF826822 - 1 - - - - - - - - - 1 
KF826839 - - - - 1 - 6 - - - 3 10 
KF826857 - - - - - - - - - 1 1 2 
KF826843 - - - - - - 1 1 - - - 2 
KF530262 7 - - - - - 1 1 1 - 2 12 
KF826851 - - - - - - 1 1 1 - 1 4 
KF530266 - - - - - - - - - 1 1 2 
KF530259 - - - - - - - - - - 2 2 
KF826845 1 1 - - 1 - 5 1 - - - 9 
KF826835 - - - - - - - - - - - 0 
KF826860 - - - - - - 3 1 - - 1 5 
KF826834 - - - - - - - - - - - 0 
KF826844 - - - - - - - - - - - 0 
KF826820 - - - - - - - - - - - 0 
KF826825 - 1 1 1 - 1 2 2 1 - 5 14 
KF826858 - - - - 1 - 2 - - 1 1 5 
KF826829 1 1 1 - - - 2 2 1 2 10 20 
 
? ???
??? ??????????????????????????
Susceptibility to RSV is the result of the interplay between host, pathogen and the 
environment, and the pathogen genetic variability can play a role in disease outcome. Most 
previous RSV genomic studies focused on partial coding sequences from laboratory 
strains, and mainly on the attachment glycoprotein (Gpr) (16, 17), which is the most 
variable protein in the RSV genome. Till 2011, only 6 full RSV genomes of non-laboratory 
strains were reported. During the past three years however, with the widespread availability 
of high-throughput sequencing technologies, many more RSV genomes became available. 
Currently there are 739 full RSV genomes available in Genbank. These data provide a 
valuable resource for better understanding of RSV evolution as well as development of 
better diagnostic test for RSV. Yet, there has been no report using full RSV sequence to 
study the signatures of virulence in RSV genome. 
This study is a pilot exploration of the role of RSV genetic variation in the most severe 
clinical cases. The two RSV genomes sequenced in this study, isolated from ICU 
hospitalized, previously healthy children, were shown to belong to the main globally 
circulating clades of RSV and to be highly similar to RSV isolated from non-extreme cases 
at both the DNA and protein levels. We did not identify any single nucleotide or structural 
variant that could confer increased virulence to the virus. However, an obvious limitation of 
our pilot study is an extremely limited number of sequenced genomes, making it impossible 
to exclude an impact of RSV genomic variation in pathogenesis. We have isolated an 
additional 57 RSV genomes from patients with severe clinical presentation of RSV 
infection, for which host exome sequencing data is also available. This phenotypically 
homogeneous collection of RSV strains from the most extreme cases of RSV infection will 
provide a valuable resource to explore the role of RSV genetic variation in susceptibility 
and clinical outcome of the infection. Sequencing of these viruses and combining the result 
of viral sequencing study with the available host genomic data is needed to get a 
comprehensive picture of severe susceptibility to RSV. The current study provides a 
general framework for this research. 
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Inter-individual variability is a well-known but poorly understood characteristic of infectious 
diseases. The work presented in this thesis provides conclusive evidence for the role of 
rare human genetic variants in susceptibility to life-threatening Pseudomonas aeruginosa 
(P. aeruginosa) and respiratory syncytial virus (RSV) infections in otherwise healthy 
children. In parallel, it provides a framework for exploring viral genetic variation using high-
throughput sequencing (HTS) technology. 
In chapter two, I tested the hypothesis that severe sepsis due to community-acquired P. 
aeruginosa in previously healthy children can reflect an underlying immunodeficiency. I 
used exome sequencing to search for primary immunodeficiency in 11 children with P. 
aeruginosa bacteraemia. I identified mutations leading to known immunodeficiencies in two 
fatal cases: X-linked agammaglobulinemia due to a novel BTK mutation and ICF 
immunodeficiency syndrome due to a novel DNMT3B mutation. I concluded that severe P. 
aeruginosa sepsis in children without clinical risk factors can represent the first 
manifestation of a previously unrecognized primary immunodeficiency. 
In chapter three, I tested the hypothesis that rare genetic variations can explain the clinical 
severity of common viral respiratory infections in previously healthy children. 120 
previously healthy children requiring intensive care support because of a severe illness 
caused by a respiratory virus were recruited. After exome sequencing, I identified three 
rare loss-of-function variants in IFIH1. Functional characterization of the variants 
demonstrated that the mutated proteins are unable to induce interferon-β, are intrinsically 
less stable than wild-type IFIH1, and lack ATPase activity. Experiments also showed a 
dominant negative effect of the mutated proteins on wild-type IFIH1 stability and ATPase 
activity. In vitro assays showed effective restriction of human respiratory syncytial virus and 
rhinovirus by IFIH1. I concluded that IFIH1 deficiency causes a primary immunodeficiency 
manifested in extreme susceptibility to common respiratory RNA viruses. 
In chapter four, I performed a pilot study for exploring RSV genetic variation. The main goal 
of this work was to set up a framework for analysing HTS data derived from the pathogen 
genome. Two RSV strains were isolated from nasopharyngeal aspirates (NPA) of two 
previously healthy children with severe clinical presentation of RSV infection. After 
sequencing, I used bioinformatic analysis to reconstruct the RSV genome for each strain 
and to compare them at the RNA and protein level with strains isolated from routine cases 
of RSV infection. The analysis showed that these two RSV genomes belonged to the most 
prevalent clades. I did not find any variation at RNA or protein level that can explain the 
unusual severe outcome of RSV infection in the selected patients. However, given the high 
variability of RSV genome and the small size of this study, one cannot exclude an impact of 
RSV genomic variation on pathogenesis and clinical outcome.  
? ???
The results presented in chapters two and three of this thesis demonstrate that exome-
sequencing is a powerful tool to study the genetic basis of infectious disorders and 
highlights the power of extreme phenotype sampling in sporadic cases for gene discovery. 
The prototype study I described in chapter four can be extended to large-scale studies 
aiming at establishing a link between pathogen genome variation and disease severity. 
Pathogen genomic studies in combination with host genomic studies can provide a more 
comprehensive picture of host-pathogen interaction and consequently lead to development 
of better preventive and therapeutic measures. 
In our host genomics studies, causal mutations were found and confirmed in 18% (for P. 
aeruginosa infection) and 7% (for RSV infection) of cases.  While non-genetic and 
pathogen-related factors could explain some of the remaining cases, we cannot rule out the 
possibility of other human genetic factors being involved. Larger sample sizes in 
combination with functional follow-up of new candidate variants is required to find 
pathogenic variants in these cases. Furthermore, whole genome sequencing is needed to 
explore the non-coding variants, large structural variants and also exonic variants that 
might not be well covered using current exome capture kits. An obvious limitation of our 
pathogen genomics study is the extremely limited number of sequenced genomes. We 
have isolated an additional 57 RSV genomes from patients with severe clinical 
presentation of RSV infection. Sequencing of these additional RSV genomes and 
combining the results with our data from host genomics of RSV infection is a necessary 
next step in our efforts to study the role of RSV genetic diversity in disease severity. 
Although the role of heritable factors in infectious diseases has been suspected for a long 
time, it’s only during the past decade that multiple studies were published that 
demonstrated the importance of host genetics in the pathogenesis of several infectious 
diseases. During the same period, the maturation and democratization of high-throughput 
sequencing technologies has made it possible to run pathogen genomic studies that have 
widened and sharpened our understanding of the genetic diversity of pathogens, a 
necessary step toward deciphering the role of pathogen genetic variability in disease 
pathogenesis. Because of the unremitting nature of the evolutionary arms race between 
host and pathogen, infectious diseases will continue to be part of the human experience. 
By promising a more fundamental understanding of the genetic contributors to infection 
outcomes, the current genomic era has the potential to bring better preventative and 
therapeutic strategies to individuals and populations. 
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